Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
04/2012 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/26/2012 > 152 patent applications in 119 patent subcategories. category listing, related patent applications

20120101021 - Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy: This invention discloses a method of and composition for treating a PE-type disorder in a subject in need of such treatment comprising administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a TTR polypeptide in admixture with a pharmaceutically acceptable vehicle.... Agent:

20120101023 - Method of diagnosing bladder cancer: The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level... Agent: Erasmus University Medical Center Rotterdam

20120101024 - Methods and compositions for differentiating embryonic stem cells: Methods and compositions for differentiating mammalian stem and progenitor cells are provided. More particularly, methods and compositions for obtaining neural cells from human embryonic stem cells are provided.... Agent: Regenerative Research Foundation

20120101022 - Self-assembling peptides bearing organic electronic functionality and applications employing the same: The aqueous self-assembly of oligopeptide-flanked π-conjugated molecules into discrete one-dimensional nanostructures is described. Unique to these molecules is the fact that the π-conjugated unit has been directly embedded within the peptide backbone by way of a synthetic amino acid with π-functionality that is compatible with standard Fmoc-based peptide synthesis or... Agent: The Johns Hopkins University

20120101025 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120101026 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120101027 - Inhibition of secretion from non-neuronal cells: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of... Agent: Syntaxin Limited

20120101028 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Yale University

20120101029 - Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the... Agent: Rappaport Family Institute For Research In The Medical Sciences

20120101030 - Caspofungin composition: The present invention relates to a composition comprising caspofungin or a pharmaceutical acceptable salt thereof and succinate or lactate as a buffering agent.... Agent: Xellia Pharmaceuticals Aps

20120101031 - Macrocyclic hepatitis c serine protease inhibitors: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs... Agent: Abbott Laboratories

20120101032 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of... Agent: Intermune, Inc.

20120101033 - Retinitis pigmentosa treatment: A method of treatment of retinitis pigmentosa using a medically effective dose of insulin, IGF-1, and chlorin e6 topically applied to the conjunctival sac of the afflicted eye. The combination of these is very effective in treating retinitis pigmentosa and may be repeated as directed by a medical practitioner. The... Agent:

20120101034 - Process for solubilizing glucagon-like peptide 1 compounds: Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution.... Agent:

20120101036 - Novel cellular factor-containing solution compositions: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.... Agent: Stemnion, Inc.

20120101035 - Vegf antagonist formulations: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.... Agent: Regeneron Pharmaceuticals, Inc.

20120101037 - Glucose-dependent insulinotropic peptide analogs: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.... Agent:

20120101038 - Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes: The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth,... Agent: The General Hospital Corporation

20120101039 - Calcium-sensing receptor-active compounds: A compound of general formula I their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, methods of treating diseases with said compounds, and the use of said compounds... Agent: Leo Pharma A/s

20120101040 - angiogenesis inducing agent comprising recombinant gelatin: An object of the present invention is to provide a biologically safe and highly bioadhesive angiogenesis inducing agent. The present invention provides an angiogenesis inducing agent which comprises a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.... Agent: Fujifilm Corporation

20120101041 - Polyionic dendrimer and hydrogel comprising same: Provided is a hydrogel which comprises water as the main component at a high water content and has mechanical strength suitable for practical use and which exhibits high transparency and self-healing and shape-retaining properties. Also provided are both a material for the hydrogel and a novel polyionic dendrimer. A polyionic... Agent: Japan Science And Technology Agency

20120101042 - Agents and methods for tissue repair and regeneration: Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.... Agent: The Brigham And Women's Hospital, Inc.

20120101043 - Delta-opioid receptor selective analgesics: Methods and materials are provided for the production of glycosylated peptides that exhibit high affinity and specificity for delta opioid receptors. The methods and materials of the present invention may be used for treatment of conditions involving pain, such as acute pain and nociceptic pain, neuralgia and myalgia.... Agent: Biousian Biosystem, Inc.

20120101044 - Gold (iii) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents: The invention concerns Au(III) complexes of the type [AuIIIX2(Pdtc)] (X=halogen, pseudo-halogen; pdtc=peptide-/esterified peptidedithiocarbamato) which are able to both maintain the antitumor properties and the lack of nephrotoxic side-effects of the previously reported Au(III)-dithiocarbamato complexes, together with an improved bioavailability through the peptide-mediated cellular internalization. The Au(III) complexes described have shown... Agent: Universita' Degli Studi Di Padova

20120101045 - Transducible delivery of nucleic acids using modified dsrna binding domains: The disclosure provides fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject. The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated... Agent: The Regents Of The University Of California

20120101046 - Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide: Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ... Agent: Santen Pharmaceutical Co., Ltd.

20120101047 - Peptidomimetic macrocycles: The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease.... Agent: Aileron Therapetics Inc.

20120101048 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120101050 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120101049 - Pharmaceutical composition of a potent hcv inhibitor for oral administration: A pharmaceutical composition of the following Compound (1), a potent hepatitis C viral (HCV) inhibitor, or a pharmaceutically acceptable salt thereof, for oral administration.... Agent: Boehringer Ingelheim International Gmbh

20120101051 - Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical compositions comprising same: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic... Agent: Green Cross Corporation

20120101052 - 15-thia steroid compounds and compositions: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.... Agent:

20120101053 - Cathepsin cysteine protease inhibitors for the treatment of various diseases: The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds... Agent:

20120101054 - Novel sodium channel blocking compounds tetrodotoxin galactopyranosides: Novel sodium channel blocking compounds tetrodotoxm galactopyranosides of formula I were isolated and purified by HPLC and identified further through IR, NMR, GC, and MS. The compounds have a galactopyranosyl moiety attached to C11 of tetrodotoxin and retain the analgesic activity of the latter. Pharmaceutical compositions and medical uses thereof... Agent: Wex Medical Limited

20120101055 - Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in... Agent:

20120101056 - Medicinal cream made using framycetin sulphate and chitosan and a process to make the same: The present invention is directed to a composition for treating bacterial skin infections, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and an antibacterial active ingredient. It discloses a composition for treating fungal skin infections along with skin rejuvenation containing a)... Agent: Apex Laboratories Private Limited

20120101148 - lipid formulation: The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3... Agent: Alnylam Pharmaceuticals, Inc.

20120101147 - Inhibition of hdac2 to promote memory: The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished by inhibiting HDAC2 and or selectively inhibiting HDAC1/2 or HDAC1/2/3.... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20120101149 - Betulinic acid derivatives and methods of use thereof: This invention features betulinic acid derivatives having the formula: wherein the variables are defined herein. The invention also provides related compounds and intermediates thereof, as well as pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Treatment methods and methods of manufacture are also provided.... Agent:

20120101150 - Use of vgii3 activity modulator for the modulation of adipogenesis: The present invention concerns Vgll3 a new target involved in adipogenesis modulation. Further, the present invention relates to methods to increase Vgll3 activity in adipocytes and preadipocytes. In addition, pharmaceutical composition comprising Vgll3 activity enhancing molecules in order to enhance the Vgll3 activity in a target tissue are also provided.... Agent: Sanofi

20120101057 - Combined therapy of colorectal carcinoma: The invention relates to a combined therapy, wherein addition of a vitamin D analogue to the standard treatment regimen based on cytostatics, 5-fluorouracil and/or its precursors, generates potential possibility of achieving beneficial therapeutic effect in the first-line chemotherapy or adjuvant therapy of colorectal carcinoma. Vitamin D analogues are selected from... Agent: Instytut Farmaceutyczny

20120101058 - Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease: A pharmaceutical composition for preventing or treating lifestyle-related disease is provided. Also provided is a food useful for the prevention or treatment of lifestyle-related disease. The pharmaceutical composition contains, as an active ingredient, a sugar in which a mannose unit makes up 66% or more in terms of the number... Agent:

20120101060 - Skin protectant, particularly against hydrophobic (lipophilic) and against hydrophilic (lipophobic) harmful substances: The invention relates to a skin protectant, particularly against hydrophobic (lipophilic) and hydrophilic (lipophobic) harmful substances, obtainable by means of an amount of at least one barrier-forming component, particularly against hydrophobic (lipophilic) harmful substances, wherein the nephelometric turbidity unit of the barrier-forming component is determined by means of turbidimetry and... Agent: Evonik Stockhausen Gmbh

20120101059 - Sulphated hyaluronic acids as regulator agents of the cytokine activity: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with... Agent: Fidia Farmaceutici S.p.a.

20120101061 - Compositions and methods for the treatment of inflammation: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.... Agent:

20120101062 - Lipase inhibitors: The present invention relates to inhibitors of lipases, such as inhibitors of endothelial lipase, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. The prototype of these inhibitors has lipophilic portion and an electrophilic site.... Agent: Trustees Of Tuffs College

20120101063 - Biocidal aldehyde composition: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide, alcohol, and functional excipients for surface-sterilization of medical instruments and other objects. The quaternary phosphonium biocide is preferably TTPC, and the alcohol isopropyl alcohol. The OPA is the dialdehyde C6H4(CHO)2, which produces an inherent bacteriostatic effect, lowering surface tension, and aiding... Agent:

20120101064 - Imidazole derivatives and their use as modulators of cyclin dependent kinases: wherein Q is CH or N; X is N, N+—O− or CR3; Y is N, N+—O− or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form... Agent: Novartis Ag

20120101065 - Inhibitors of tyrosine kinases and uses thereof: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated... Agent: Pharmacyclics, Inc.

20120101066 - Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound: A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipients, wherein X, R,... Agent:

20120101067 - Methods for enhancing hematopoietic progenitor cell engraftment: Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits... Agent: Children's Medical Center Corporation

20120101068 - Diphenyl sulfide derivatives and medicines containing same as active ingredient: Provided are diphenyl sulfide derivatives which have excellent S1P3 antagonistic activity and are useful as drugs. Intensive studies have been made for the purpose of creating a compound having S1P3 antagonistic activity. As a result of the intensive studies, it has been found that diphenyl sulfide derivatives represented by general... Agent:

20120101069 - Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds: The present invention relates to a haemodialysis solution or concentrate thereof comprising creatine compound(s) and the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof. Furthermore, the present invention is directed to a method for preparing creatine-containing dialysis solutions and concentrates. In addition, the present invention is... Agent: Crearene Ltd.

20120101070 - 11a, 12-derivatives of tetracycline compounds: 11a,12-dehydrotetracycline compounds are described.... Agent: Paratek Pharmaceuticals, Inc.

20120101071 - Substitutedtetracycline compounds for the treatment of malaria: This invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amount of a substituted tetracycline compound, such that malaria is treated or prevented. In one aspect, the invention relates to pharmaceutical compositions which include an effective amount of... Agent: Paratek Pharmaceuticals, Inc.

20120101072 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to... Agent: Synta Pharmaceuticals Corp.

20120101076 - Carbonate derivatives for the treatment of cough: The invention relates to use of certain quinuclidine carbonate derivatives as cough suppressants, particularly for treating patients with upper respiratory tract infections or asthma.... Agent: Chiesi Farmaceutici S.p.a.

20120101074 - Method and medication for prevention and treatment of ocular hypertension and glaucoma: An effective dose of a pharmaceutically acceptable phenylbutyrate salt such as sodium phenylbutyrate applied to human ocular tissues or through injection or other means prevents ocular hypertension and treats glaucoma in humans, leading to a new medical therapy for lowering the intraocular pressure via a mechanism different from the existing... Agent: The Chinese University Of Hong Kong

20120101073 - Novel method for treating breathing disorders or diseases: The present invention includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising (+)-doxapram or a salt thereof, and a pharmaceutically acceptable carrier, wherein the formulation is essentially free of... Agent: Galleon Pharmaceutical, Inc.

20120101075 - Method and medication for prevention and treatment of ocular hypertension and glaucoma: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.... Agent: Laboratorios Almirall, S.a.

20120101077 - Agglomerate formulations useful in dry powder inhalers: Several embodiments of the present invention provide for an agglomerate useful for an agglomerate based dry powder inhaler comprising at least one active pharmaceutical agent, at least one additional functional excipient and at least one excipient, such as a binder. Useful at least one additional functional excipients include but are... Agent: Schering Corporation

20120101078 - Amide derivatives as neuropeptide y5 receptor ligands: Disclosed are a series of neuropeptide Y Y5 receptor ligands, and as such are useful to treat disorders related to mood, stress, ADHD, cognition, stress and dementia.... Agent: H. Lundbrck A/s

20120101080 - Composition for treatment of tuberculosis: The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein R1 is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; R2 is (CH2)n wherein n is 0, 1, 2, 3 or 4; R3 is (CH2)mR3A wherein m is 0, 1, 2, 3 or 4,... Agent: Bioversys Ag

20120101081 - Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors: e

20120101083 - S1p1 agonists comprising a bicyclic n-containing ring: The present invention relates to novel compounds of formula (I) having S1P1 agonist activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxo Group Limited

20120101082 - Vasopressin v1a antagonists: The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.... Agent:

20120101079 - Substituted 6-amino-nicotinamides as kcnq2/3 modulators: Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.... Agent: Grunenthal Gmbh

20120101084 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an... Agent: Osi Pharmaceuticals, LLC

20120101085 - Compounds and methods for modulating activity of calcium release channels: The present teachings provide compounds of Formulae I and II: and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1′, R2, R2′, R3, R3′, and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods... Agent: State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State Univ.

20120101086 - Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors: The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxo Group Limited

20120101087 - Generation of combinatorial synthetic libraries and screening for novel proadhesins and nonadhesins: The present invention relates to, in part, novel bisphenol compounds useful for the recognition, attachment and growth of unwanted biologics on natural and manmade surfaces. Another aspect of the invention relates to combinatorial libraries for producing the same. Another aspect of the invention relates to pharmaceutical formulations comprising the same.... Agent:

20120101088 - Transmembrane penetration enhancer: A transmembrane penetration enhancer includes a thermotropic liquid crystal suitably prepared for use in a therapeutic system to improve delivery of at least one active ingredient across a biomembrane and/or skin. The thermotropic liquid crystal comprises at least one cholesteryl ester and is effective in a mesomorphic state at a... Agent:

20120101089 - Anti-emetic substance: The present invention provides a therapeutic solution for effective control of symptoms related to nausea and vomiting. The therapeutic solution is a pharmaceutical composition which combines anti-emetics of different classes. These classes include dopamine receptor antagonists, serotonin receptor antagonists, butyrphenones, and neurokinin receptor antagonists. The combination of different anti-emetics mitigates... Agent:

20120101090 - Crystal of a benzoxazinone compound: Disclosed is a crystal of 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one useful as a preventive or therapeutic agent for obesity and the like. Specifically disclosed is a crystal of 2-hexadecyloxy-6-methyl-4H-3, 1-benzoxazin-4-one having a powder X-ray diffraction pattern in which characteristic peaks appear at powder X-ray diffraction interplanar spacings (d) of around 16.54±0.2, 13.26±0.2, 4.70±0.2, 4.38±0.2,... Agent: Norgine B. V.

20120101092 - Small molecule inhibitors of mdm2 and the uses thereof: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).... Agent: The Regents Of The University Of Michigan

20120101091 - Viral polymerase inhibitors: The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other... Agent: Boehringer Ingelheim International Gmbh

20120101094 - Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands... Agent:

20120101093 - Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors: The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is... Agent: High Point Pharmaceuticals, LLC

20120101095 - Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators: e

20120101096 - Compounds and methods for treating mammalian gastrointestinal microbial infections: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The... Agent: Brandeis University

20120101098 - 3,28-disubstituted betulinic acid derivatives as anti-hiv agents: Compounds according to Formula (I) are described along with compositions containing the same and methods of use thereof for the treatment of viral infections.... Agent:

20120101097 - Aryl sulfonamides: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.... Agent:

20120101099 - Histone deacetylase inhibitors: The disclosure provides compounds of formula I and methods for preparation thereof. The compounds act as inhibitor of histone deacetylase.... Agent: Anthem Biosciences Private Limited

20120101100 - Heterocyclic urea derivatives and methods of use thereof-211: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent:

20120101101 - Therapeutic agent for motor disorders: Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for... Agent: Kyowa Hakko Kirin Co., Ltd.

20120101102 - Method for predicting therapeutic effect of chemotherapy on renal cell cancer: The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to... Agent: Taiho Pharmaceutical Co., Ltd.

20120101103 - 7-phenoxychroman carboxylic acid derivatives: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis,... Agent: Array Biopharma Inc.

20120101105 - Aryl substituted carboxamide derivatives as calcium or sodium channel blockers: The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Nav1.3 and Nav1.7, and which are useful in the treatment or prevention... Agent:

20120101106 - Tetrahydronapthyridine orexin receptor antagonists: The present invention is directed to tetrahydronapthyridine and tetrahydropyridopyrazine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent:

20120101104 - Topical gel compositions and methods of use: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and paraben, and are substantially free of paraben crystalline particles after an extended period of storage.... Agent: Galderma S.a.

20120101107 - Piperazine dithioctate and pharmaceutical composition comprising the same: The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition... Agent: Celltrion Chemical Research Institute

20120101108 - Anaplastic lymphoma kinase in kidney cancer: The invention provides methods to identify, diagnose, and treat kidney cancer through the detection of expression and/or activity of anaplastic lymphoma kinase (ALK). The detection of the presence of a polypeptide with ALK kinase activity (e.g., by detecting expression and/or activity of the polypeptide), identify those kidney cancers that are... Agent: Cell Signaling Technology, Inc.

20120101110 - Diaza-spiro[5.5]undecanes: e

20120101109 - Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4-[1, 3, 4-oxadiazole-2-yl] phenyl) pyridine-3- sulphonamide: N-(3-Methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt and its uses are described.... Agent: Astrazeneca Ab

20120101111 - Novel oxazolidinone deriviatives: The present invention relates to oxazolidinone derivatives of formula (I) wherein Y, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their... Agent:

20120101112 - Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators: This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20120101113 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120101114 - Inhibitors of bruton's tyrosine kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120101115 - Compounds for inducing cellular apoptosis: The present invention provides isoquinoline, tetrahydroisoquinoline and tetrahydropyridopyrimidine compounds that induce cell death by apoptosis and uses of the compounds in medicine, especially their use for treating cancer and other diseases.... Agent: Queen Mary And Westfield College

20120101116 - Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof: The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R1 to R11 and X are defined... Agent: Medolution Limited

20120101117 - Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer: The invention provides compounds of formula I: wherein A, B, X, and Y have any of the values defined in the specification, as well as pharmaceutical compositions comprising such compounds, processes for preparing such compounds, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.... Agent:

20120101118 - Tamper resistant dosage forms: Tamper resistant controlled release formulations.... Agent: Euro-celtique S.a.

20120101119 - N-substituted indenoisoquinolines and syntheses thereof: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.... Agent:

20120101120 - Pure isomers of tritoqualine: The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. 2 and FIG. 3.... Agent:

20120101121 - drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-b) indoles, its pharmacological compound and application method: Compositions based on hydrogenated pyrido[4,3-b]indoles (variants) of formula (1) or formula (2): are provided, as are methods and kits using those compositions for the treatment of anxiety or mood disorders characterized by stresses, anxiety, neuroses, obsessive fears and their consequences.... Agent: Medivation Neurology ,inc.

20120101124 - 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists: 1,2,4-Oxadiazol derivatives represented by formula (I) useful as sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated via S1P1 receptor are disclosed.... Agent: Glaxo Group Limited

20120101123 - Compounds: The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent:

20120101122 - Imidazo[1,2 a] pyridine 6 carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture: e

20120101125 - Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is... Agent: High Point Pharmaceuticals, LLC

20120101126 - Crystalline forms of pitavastatin calcium: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous... Agent: Nissan Chemical Industries Ltd.

20120101127 - Novel tetrahydroquinoline derivatives: and pharmaceutically acceptable salts or esters thereof, wherein R1 to R7 have the significance given herein. The compounds are activators of AMP-activated protein kinase (AMPK) and are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type... Agent:

20120101129 - Methylphenidate derivatives and uses of them: d

20120101128 - Perhexiline for treating chronic heart failure: Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure may be non-ischaemic or ischaemic. Also disclosed is the use of... Agent: Heart Metabolics Limited

20120101130 - Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug: Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit... Agent: Adolor Corporation

20120101131 - Aminotetrahydroindazoloacetic acids: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of... Agent:

20120101132 - New substituted oxindole derivative: 6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form, pharmaceutical formulations containing said compounds, to the use of said active compounds in therapy, and methods of prevention and/or treatment of conditions associated with glycogen synthase kinase-3 related disorders, comprising administering to a mammal, including... Agent:

20120101133 - Process for preparing tetrazole-substituted anthranilamide derivatives and novel crystal polymorphs of these derivatives: (

20120101134 - 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists: 5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.... Agent: Glaxo Group Limited

20120101135 - Composition containing sorbitan monocaprylate and antimicrobial substances: The invention relates to liquid compositions which contain a) from 40 to 99.9% by weight of sorbitan monocaprylate and b) from 0.1 to 60% by weight of one or more antimicrobial substances selected from the group consisting of the components b1) to b5): b1) specific organic acids and the salts... Agent: Clariant Finance (bvi) Limited

20120101136 - 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists: 5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.... Agent: Glaxo Group Limited

20120101137 - Novel thiophenecarboxamide derivative and pharmaceutical use thereof: m

20120101138 - Fluorinated aminotriazole derivatives:

20120101139 - Econazole composition and methods of treatment therewith: The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation.... Agent: Quinnova Pharmaceuticals, Inc.

20120101140 - Econazole composition and methods of treatment therewith: The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation.... Agent: Quinnova Pharmaceuticals, Inc.

20120101141 - Gel compositions and methods of use: Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.... Agent: Galderma R&d Snc.

20120101142 - Ready to use ketorolac formulations: p

20120101143 - Compounds having activity in increasing ion transport by mutant-cftr and uses thereof: The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., DF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may... Agent:

20120101144 - Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof: Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.... Agent:

20120101145 - Oligomer-containing pyrrolidine compounds: The invention relates to (among other things) oligomer-containing pyrrolidine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.... Agent: Nektar Therapeutics

20120101146 - Pharmaceutical composition comprising rotigotine salts (acid or na), especially for iontophoresis: The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol (rotigotine), their use as a medicament, for example for the treatment of CNS disorders like Parkinson Disease, RLS, fybromyalgia and/or depression, in particular through electromotive administration. The present invention relates to pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery... Agent: Ucb Pharma Gmbh

20120101151 - Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof,... Agent: The Royal Institution For The Advancement Of Learning/mcgill University

20120101152 - Neurite elongation agent, memory-improving agent and anti-alzheimer agent comprising 4'-demethylnobiletin or 4'-demethyltangeretin as active ingredient, and process for production of the compound: A method for producing 4′-demethylnobiletin or 4′-demethyltangeretin including fermenting a skin derived from at least one citrus fruit selected from citrus fruits belonging to section Acrumen in subgenus Metacitrus in genus Citrus or citrus fruits belonging to section Aurantium in subgenus Archicitrus in genus Citrus, or a water extract product... Agent:

20120101153 - Rocaglaol derivatives as cardioprotectant agents and as antineoplastic agents: The present invention discloses new rocaglaol derivatives and the use of rocaglaol derivatives to prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent.... Agent: Universite De Strasbourg

20120101154 - Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism: Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.... Agent: Tonix Pharmaceuticals, Inc.

20120101155 - Zinc salt compositions for the prevention of dermal and mucosal irritation: The present invention provides for compositions and methods that may offer protection from irritants as well as antimicrobial protection. Preferred embodiments of the invention include topical antimicrobial compositions that lack conventional antibiotics or preservatives, wherein the antimicrobial benefit is created by essential oils (or their active ingredients), emollient solvents and,... Agent:

20120101156 - Compositions comprising a retinoid and an nfkb-inhibitor and their methods of use: A composition including a retinoid, an NFκB-inhibitor, and a cosmetically-acceptable topical carrier is provided. Methods of treating the skin are also provided.... Agent:

20120101157 - 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and preparations thereof: wherein R1 group is H, CH3, or C2H5; R2 group is H, or Br; R3 group is CH3, or C3H7; and R4 group is H, or C(═NH)—NH2. 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives provided here were non-toxic to MDCK cells, particularly compounds 6a, 6b, 6c, 6e, 6f, 7a, 7b and 8 had better... Agent: National Defense Medical Center

20120101158 - Surface anesthetic agent: Provided is an anesthetic agent which can exhibit an anesthetic effect rapidly when adhered on mucosal membranes, the skin or the like by means of application or the like in local anesthesia, particularly surface anesthesia. Prepared are: a fast-acting surface anesthetic agent containing lidocaine and ethyl paraaminobenzoate at a specific... Agent: Yamaguchi University

20120101159 - Ibuprofen lysinate oral suspension: The present invention refers to an ibuprofen lysinate-based pharmaceutical composition in the form of oral suspension and to the preparation procedure thereof.... Agent: Laboratorio De Aplicaciones Farmacodinamicas, S.a.

20120101160 - Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteins: The present invention provides methods for treating glaucoma by administering compounds capable of stabilizing misprocessed or misfolded proteins that are responsible for the condition.... Agent: Alcon, Inc.

20120101161 - Fatty acid analogues for the treatment of inflammatory and autoimmune disorders: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an... Agent: Life Science Nutrition As

20120101162 - Methods and compositions for inducing physiological hypertrophy: Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition. In certain embodiments methods and compositions involve an aquaporin 7inducer.... Agent: The Regents Of The University Of Colorado, A Body Corporate

20120101163 - Composition for inhibiting cancer metastasis: t

20120101164 - Abscission and crop storage unit: A composition comprising a compound selected from an auxin, an auxin precursor, an auxin metabolite or a derivative of said auxin, auxin precursor or auxin metabolite or a mixture thereof and optionally acetaminophen or a derivative thereof for improving post-harvest storability of crops.... Agent: Taminco, Naamloze Vennootschap

20120101165 - Urea compositions with cooling effect: The present invention includes a urea powder, the particles of which are protected in a dimethicone and silica mixture, prior to being incorporated into anhydrous compositions. The protected urea is capable of imparting a cooling activity to a topical composition. The invention also pertains to topical, cooling compositions containing a... Agent:

20120101166 - Composition and method for irrigation of a prepared dental root canal: Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection.... Agent: The University Of British Columbia

20120101167 - Treatment of ocular and cerebral ischemia: Ocular and cerebral blood flow are enhanced by the administration of (−) erythro isomer of α-methyl epinephrine, a C1 to C8 aliphatic ester of α-methyl epinephrine, α-methyl norepinephrine, a C1 to C8 aliphatic ester of α-methyl norepinephrine, or a pharmacologically acceptable acid addition salt thereof.... Agent:

20120101168 - Deuterium enriched rasagiline: The subject invention provides deuterated rasagiline, its salts and uses.... Agent:

20120101169 - Methods of providing anticoagulation effects in subjects: The present invention is directed to methods of providing anticoagulation effects in subjects in need thereof, comprising administering to the subjects at least twice a day compounds of the present invention, stereoisomers, and racemates thereof.... Agent: Penwest Pharmaceuticals Co.

20120101170 - Polyurethane thickeners: The present invention relates to a process for preparing polyurethanes, which comprise at least three hydrophilic sections, at least four hydrophobic sections, optionally allophanate segments and/or isocyanurate segments and which are prepared in the presence of alkali(ne earth) metal carboxylates. The process may comprise using at least one carboxylic acid... Agent: Basf Se

20120101171 - Polyurethane thickeners: The present invention relates to a single-stage process for preparing polyurethanes which comprise at least three hydrophilic sections, at least four hydrophobic sections, optionally allophanate segments and optionally isocyanurate segments, in the presence of alkali(ne earth) metal carboxylates or zinc carboxylates. Furthermore, the present invention relates to the polyurethanes themselves... Agent: Basf Se

20120101172 - Liquid or pourable proteosome-forming bath and shower concentrates, galenic application products thereof, and their use: The invention relates to balneological preparations, especially bath and shower preparations, which, as a pourable or liquid premixture concentrate, contain liposome-forming components, such as phospholipids, in addition to natural and/or synthetic lipids, and are also provided as mixtures containing primarily vegetable proteins, surfactants, and optional additives. When entering in contact... Agent: Merz Pharma Gmbh & Co. Kgaa

  
04/19/2012 > 226 patent applications in 168 patent subcategories. category listing, related patent applications

20120094892 - Prodrugs: The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.... Agent: Ktb Tumorforschungsgesellschaft Mbh

20120094893 - Method of using diketopiperazines and composition containing them: e

20120094894 - Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics: The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic... Agent: Boehringer Ingelheim International Gmbh

20120094895 - Method for enhancing phagocytosis of phosphatidylserine-exposing cells: An Annexin A5 variant, comprising one or more RGD (Arg-Gly-Asp) sequences, is suitable for use in the treatment of a disease in mammals, including humans, wherein augmentation of phagocytosis is a desired effect of treatment. The Annexin A5 variant can e.g. be used in the treatment of chronic inflammatory diseases... Agent: Mosamedix B.v.

20120094896 - Inhibitors of viral integrase and methods of use: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.... Agent: Integratech Proteomics, LLC

20120094897 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I, and II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an... Agent: Intermune, Inc.

20120094898 - Peptide derivative: e

20120094899 - Neuromedin u derivative:

20120094900 - Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof: There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD.... Agent: University Health Network

20120094901 - Method for controlling the digestive coagulation of proteins: This invention relates to the coagulation of protein containing nutritional compositions in the upper gastro-intestinal tract, more in particular in the stomach and provides a method for reducing such coagulation.... Agent: N.v. Nutricia

20120094902 - Fast-acting insulin formulation: A complex between an insulin and a polysaccharide comprising carboxyl functional groups is described, the polysaccharide being chosen from polysaccharides functionalized with at least one phenylalanine derivative, noted Phe, the phenylalanine derivative being chosen from phenylalanine and its alkali metal cation salts, phenylalaninol, phenylalaninamide and ethylbenzylamine or from phenylalanine esters,... Agent: Adocia

20120094903 - Compositions for intranasal delivery of human insulin and uses thereof: What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and a thickening agent, wherein said formulation provides a ultra-rapid acting profile to regular human insulin.... Agent: Marina Biotech Inc.

20120094904 - Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof: The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturase family members. The invention also provides recombinant expression vectors containing desaturase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (LCPUFAs), e.g.,... Agent: Bioriginal Food & Science Corp.

20120094905 - Method for treating hyperglycemia with glp-1: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1... Agent: Mannkind Corporation

20120094906 - Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided... Agent: Hanall Biopharma Co. Ltd

20120094907 - Peptide therapy for increasing platelet levels: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention relates to compositions and methods for providing improved platelet levels, useful in the treatment and prevention of thrombocytopenia, for controlling bleeding and for inducing or modulating haemostasis.... Agent: Biokine Therapeutics Ltd.

20120094908 - Truncated activin type ii receptor and methods of use: The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of... Agent: The Johns Hopkins University School Of Medicine

20120094909 - Fibronectin based scaffold domain proteins that bind to pcsk9: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or... Agent: Bristol-myers Squibb Company

20120094910 - Improved process for the preparation of desmopressin or its pharmaceutically acceptable salts: The present invention relates to a novel and improved process for the preparation of 1-deamino-8-D-arginine vasopressin (Desmopressin) or its pharmaceutically acceptable salts thereof and also relates to an improved process for the purification of Desmopressin or its pharmaceutically acceptable salts. Further, the present invention also relates to pharmaceutical composition of... Agent:

20120094911 - Endokinin c/d-derived peptides: e

20120094912 - Malpeg-hb conjugate-containing compositions for delivering carbon monoxide (co) to cells: The present invention relates to compositions for delivering carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver CO to cells.... Agent: Sangart, Inc.

20120094913 - Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially... Agent: Bethesda Pharmaceuticals, Inc.

20120094914 - Prophylactic or therapeutic agent for rheumatoid arthritis or rheumatoid arthritis-related diseases: (b) A protein consisting of the amino acid sequence of SEQ ID NO: 1 with the deletion, substitution, or addition of one or several amino acids excluding the amino acid at position 42, and having a binding activity for leukocyte Ig-like receptors and/or CD8... Agent: Kyushu University, National University Corporation

20120094916 - Altering memory by affecting staufen function: The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or STAUFEN function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating staufen-dependent... Agent:

20120094915 - Anti-mental fatigue drug: To provide anti-mental fatigue drugs as well as foods, beverages, and fodders that can be taken daily and effective for relieving mental stress and inducing relaxation by intake. An anti-mental fatigue drug containing iron-binding lactoferrin as an active ingredient and foods, beverages, and fodders containing the drug.... Agent: Megmilk Snow Brand Co., Ltd.

20120094917 - Iap inhibitors: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.... Agent: Tetralogic Pharmaceuticals Corp

20120094918 - Method of using diketopiperazines and composition containing them: e

20120094920 - Cosmetic and/or pharmaceutical composition comprising a peptidic hydrolyzate that can reinforce the barrier function: The invention relates to a peptidic hydrolyzate enriched in bioactive peptide, capable of reinforcing the skin barrier function and stimulating epidermal differentiation. The invention is also relative to a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, said hydrolyzate as active principle. The invention further relates to the... Agent: Isp Investments Inc.

20120094921 - Cosmetic and/or pharmaceutical composition comprising a relieving peptidic hydrolyzate: The invention concerns a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, a peptide hydrolyzate which is enriched in soothing bioactive peptide. The invention also concerns the use, in a cosmetic composition, of the active principle in accordance with the invention to activate HMG-CoA reductase in skin cells... Agent:

20120094919 - Use of tripeptides: The present invention relates to the use of tripeptide derivatives for tightening, firming and/or moisturizing skin. Furthermore, the invention relates to a method for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue and/or proteoglycans by fibroblasts and/or keratinocytes such as in particular the synthesis of Hyaluronic acid... Agent:

20120094922 - Screening assays for agents that alter inhibitor of apoptosis (iap) protein regulation of caspase activity: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The... Agent: Sanford-burnham Medical Research Institute

20120094923 - Methods and materials for assessing prostate cancer recurrence and reducing mesotrypsin activity: This document provides methods and materials involved in assessing prostate cancer recurrence and reducing mesotrypsin activity. For example, methods and materials for using expression levels of PRSS3 nucleic acid to determine whether a prostate cancer patient having undergone prostatectomy is likely to experience prostate cancer recurrence are provided. In addition,... Agent:

20120094924 - Nucleic acid delivery compounds: Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell.... Agent: Nitto Denko Corporation

20120094925 - Insulin-like growth factor binding protein 7 for treatment of cancer: Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if the tumor has increased Ras-BRAF-MEK-Erk signaling, is dependent for growth and/or survival upon the Ras-BRAF-MEK-Erk... Agent: University Of Massachusetts

20120094926 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120094927 - Therapy for mll-rearranged leukemia: Provided are methods for treating MLL-rearranged ALL by administering to a patient an HDAC inhibitor alone or in combination with a DNA demethylating agent. Also provided are methods of treating MLL-rearranged infant ALL. Methods of treating cells by these agents are also provided. Additionally, disclosed is a method for screening... Agent:

20120094928 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120094929 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120094930 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds.... Agent: Onyx Therapeutics, Inc.

20120094931 - Compositions and methods to modulate progression and onset of inflammatory bowel disease: Embodiments herein illustrate methods and compositions for treating inflammatory bowel disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or modulating progression of an inflammatory bowel disorder in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin.... Agent:

20120094932 - Macrocyclic lactone compounds and methods for their use: b

20120094933 - Derivatives of apf and methods of use: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide... Agent:

20120094934 - Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in... Agent: Opko Curna, LLC

20120094936 - Malpeg-hb conjugate-containing compositions for delivering nitric oxide (no) to cells: The present invention relates to compositions for delivering nitric oxide (NO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver NO to cells.... Agent: Sangart, Inc.

20120094937 - Mammalian cell surface antigens; related reagents: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.... Agent: Schering Corporation

20120094935 - Methods for creating or identifying compounds that bind tumor necrosis factor alpha: Methods for creating therapeutic candidate compounds or of identifying therapeutic candidate compounds for use in treating TNFα-mediated diseases or conditions are described that utilize parameters, including amino acid residues, obtained by analysis of a Yatapoxvirus 2L-TNFα crystal structure.... Agent:

20120094938 - Small peptides and methods for treatment of chronic inflammatory bowel disease: Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory... Agent:

20120094939 - Anti-viral compounds, compositions and methods: The present invention is directed to compounds of formulae (I) and (II) and pharmaceutically acceptable forms thereof; pharmaceutical compositions thereof; and methods of treating a viral infection, such as a hepatitis C virus (HCV) infection, by administering to a subject diagnosed with or being susceptible to the viral infection a... Agent:

20120094941 - Mangiferin-berberine salt, manufacturing method and use thereof: The present invention provides a mangiferin-berberine salt and manufacturing method thereof. Otherwise, the present invention also provides the use of mangiferin-berberine salt as AMPK activator.... Agent:

20120094940 - Process of producing sugar composition comprising definite amount of target hexose and having sugar constitution different from that of starting sugar material and use of produced sugar composition: A process of producing a sugar composition comprising a definite amount of an target hexose, comprising treating a starting liquid sugar material comprising a starting sugar material hexose or a mixture comprising hexose in a system in the presence of one or more types selected from the group consisting of... Agent: Izumoring Co., Ltd.

20120094942 - Chemosensory receptor ligand-based therapies: Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation... Agent: Elcelyx Therapeutics, Inc.

20120094943 - Alpha 7 nicotinic receptor selective ligands: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations... Agent: University Of Florida Research Foundation, Inc.

20120094944 - Novel imidazopyridine compound: a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug thereof, is useful as a pharmaceutical ingredient having chymase inhibitory activity for preventing and/or treating of chymase-mediated disease, such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the like.... Agent: Ono Pharmaceutical Co., Ltd.

20120094945 - Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening: The invention relates to assays to detect selective gene regulation by ligand dependent transcription factors. The invention also relates to selective modulators of the glucocortocoid receptor for treatment of inflammation and allergic and immune-mediated diseases.... Agent: The Regents Of The University Of California

20120094946 - Glycosylated chlorambucil analogs and uses thereof: e

20120095076 - Compositions and methods for inhibiting expression of huntingtin gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The... Agent:

20120095074 - Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes: Compositions and methods for the detection and treatment of T1D are provided.... Agent:

20120095077 - Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference: Disclosed are compositions and methods related to modified nucleobases. Also disclosed are compositions and methods related to modified interfering RNAs. Also disclosed are compositions and methods related to modified guanine bases for controlling off-target effects in RNA interference.... Agent: University Of Utah Research Foundation

20120095080 - Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules: Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided.... Agent: City Of Hope

20120095078 - Methods of diagnosis and treatment of melanoma: Methods for the diagnosis or prognosis of melanoma by detecting expression of ATF2 and MITF in melanocytes are provided herein. Also provided are methods of treating a melanocyte proliferative disorder with agents that modulate the transcriptional activity of ATF2 and/or MITF activity.... Agent: Sanford-burnham Medical Research Institute

20120095075 - Novel lipids and compositions for the delivery of therapeutics: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure:... Agent: Alnylam Pharmaceuticals, Inc.

20120095081 - Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1 (PON1), in particular, by targeting natural antisense polynucleotides of Paraoxonase 1 (PON1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent:

20120095079 - Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2). The invention also relates to the... Agent: Opko Curna, LLC

20120095082 - Use of interfering rna for treating an hiv infection: The present invention relates to interfering RNAs, in particular miRNAs, capable of specifically blocking the replication of a strain of the HIV virus that is resistant to an antiretroviral compound, and use thereof for treating infections by this type of virus.... Agent: Universite Pierre Et Marie Curie (paris 6)

20120095084 - Modulation of serotonin neurons involving the pet-1 transcriptional control region: Serotonin neurons modulate most homeostatic Central Nervous System (CNS) functions while influencing the expression of behavioral traits such as mood, aggression and anxiety. Serotonin neuron dysfunction has been implicated in depression, addiction, autism and sudden infant death syndrome. This disclosure describes a straightforward, highly reproducible method for genetically accessing serotonin... Agent: Case Western Reserve University

20120095085 - Nucleic acid modulators of clec-2: Provided are ligands which bind to and regulate the function of CLEC-2. Nucleic acid CLEC-2 ligands described herein are able to inhibit CLEC-2 mediated platelet aggregation and may also provide use in regulating CLEC-2-mediated processes such as thrombus formation, tumor metastasis, lymphangiogenesis, HIV dissemination, inflammatory response, cytokine production and phagocytosis.... Agent:

20120095086 - Protein tyrosine phosphatase mutations in cancers: Tyrosine phosphorylation, regulated by protein tyrosine phosphatases (PTPs) and kinases (PTKs), is important in signaling pathways underlying tumorigenesis. A mutational analysis of the tyrosine phosphatase gene superfamily in human cancers identified 83 somatic mutations in six PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13, PTPN14), affecting 26% of colorectal cancers and a... Agent: The Johns Hopkins University

20120095083 - Use of triplex structure dna in transferring nucleotide sequences: The recombinant polynucleotide comprises a transgene placed under the control of regulatory signals for transcription and expression, regulatory signals, of lentiviral origin, for reverse transcription, expression and packaging, and a polynucleotide comprising a cis-acting central initiation region (cPPT) and a cis-acting termination region (CTS). The regions are of lentiviral origin... Agent:

20120094947 - Method for the selective therapy of disease: Methods for treating diseases in humans and vertebrate animals are provided using competitive antagonists of cellular metabolites combined with a protective agent for protecting host cells from toxic effects of the drugs. Also provided are kits comprising competitive antagonists and suitable protective agents. In addition, screening methods for identifying competitive... Agent:

20120094948 - analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general... Agent: Giuliani International Limited

20120094949 - Histone modification patterns for clinical diagnosis and prognosis of cancer: The present invention provides methods of diagnosing and providing a prognosis and therapy for cancer including, but not limited to, pancreatic cancer and responsiveness to thymidylate synthase inhibitor (e.g., 5-FU) therapy, by identifying cancers with altered histone modification patterns selected from the group consisting of H3K4me2, H3K9me2, or H3K18ac.... Agent: The Regents Of The University Of California

20120094951 - Compositions: The specification relates to compositions comprising honey and chondroitin and/or glucos amine wherein the ingredients form a stably homogeneous composition. The subject compositions are contemplated for oral use as nutraceuticals or functional food to provide health benefits to subjects in need.... Agent:

20120094950 - Nutraceutical composition and methods for preventing or treating multiple sclerosis: The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.... Agent: Trustees Of Dartmouth College

20120094952 - Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting: The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells.... Agent:

20120094953 - Process for the production of nano-fibrillar cellulose suspensions: The present invention relates to a process for the production of suspensions of nano-fibrillar cellulose by providing cellulose fibres and at least one filler and/or pigment; combining the cellulose fibres and the at least one filler and/or pigment; and fibrillating the cellulose fibres in the presence of at least one... Agent: Omya Development Ag

20120094954 - Compositions comprising at least one complex composed of a derivative of naphthoic acid and of at least one cyclodextrin and uses thereof: e

20120094955 - Method of dissolving an oxidized polysaccharide in an aqueous solution: A method of dissolving an oxidized polysaccharide in an aqueous solution using an oligomer additive is described. The resulting aqueous solution of the oxidized polysaccharide may be used in combination with an aqueous solution comprising an amine-containing component to prepare hydrogel tissue adhesives and sealants for medical and veterinary applications,... Agent: Actamax Surgical Materials LLC

20120094956 - Treatment of cancer with specific rxr agonists: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.... Agent: Io Therapeutics, Inc.

20120094957 - Inhibitors of fatty acid amide hydrolase: Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable... Agent:

20120094958 - Quinolines as inhibitors of farnesyl pyrophosphate synthase: The invention relates to a compound of formula (I) wherein the substituents are as described in the specification, which are useful as farnesyl pyrophosphate synthase modulators, e.g. in the treatment of proliferative diseases, to methods of manufacturing such compounds and to intermediates thereof.... Agent: Novartis Ag

20120094960 - Dosage forms of risedronate: Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine... Agent: Warner Chilcott Company, LLC

20120094959 - Treatment of cystic diseases: The invention described herein pertains to the treatment of cystic diseases. More particularly, the invention described herein relates to methods for treating cystic disease using one or more lysophosphatidic acid antagonists, TMEM16a inhibitors, and/or peroxisome proliferator-activated receptor modulators.... Agent:

20120094961 - Tumor eradication by inositol-tripyrophosphate: The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the... Agent: Normoxys, Inc.

20120094962 - Pharmaceutical composition for use in medical and veterinary ophthalmology: The invention relates to the manufacturing and use of pharmaceutical compositions of medicines (ophthalmic preparations) comprising a mitochondria-addressed antioxidant and a set of auxiliary substances providing effective treatment for ophtalmological diseases in humans and animals.... Agent: Mitotech Sa

20120094963 - Targeting prodrugs and compositions for the treatment of gastrointestinal diseases: Provided herein are compounds of formula (I) as well as compounds of formula (I) which are prodrugs in which the (R7)a-phenyl-S(O)2NH group represents a sulphonamide-bond compound, compositions and methods for preventing or treating gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer, wherein the method comprises delivering an effective... Agent: The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity

20120094964 - Sulfamoyl benzoic acid derivatives as trpm8 antagonists: The present invention relates to sulfamoyl benzoic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.... Agent:

20120094965 - Method and formulation for chemical peeling: A chemical peeling formulation and a formulation able to increase the efficacy and the tolerability of preparations based on the use of compounds used to carry out chemical peeling, comprising at least one keratolytic agent and dimethyl isosorbide. The composition may additionally comprise dimethyl sulphone.... Agent:

20120094967 - Compositions and methods for treating asthma and other lung diseases: The present invention provides methods for dilating the bronchi or bronchioles and relaxing a pulmonary smooth muscle in a subject by treating the subject with a pharmaceutical composition, which includes a Histone deacetylase (HDAC) inhibitor. The ability to dilate the bronchi or bronchioles and relax a pulmonary smooth muscle according... Agent:

20120094966 - Organic compounds: The present invention relates to optionally substituted 3-amino-4,5-dihydro-(1H or 2H)-pyrazolo[3,4-d]pyrimidin-6(7H)-ones and their 4-imino or 4-thioxo derivatives, e.g., 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-2H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, 3-amino-4-(thioxo or imino)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6(7H)-ones, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent: Intra-cellular Therapies, Inc.

20120094968 - Sulfonic amide and sulfoximine-substttuted diaryl-dihydropyrimidinones and usage thereof: The present application relates to novel sulfonamidw- or sulfoximine-substituted 1,4-diaryldihydropyrimidin-2-one derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment... Agent: Bayer Pharma Aktiengesellschaft

20120094969 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus... Agent: Bayer Pharma Aktiengesellschaft

20120094970 - Non-hormonal steroid modulators of nf-kb for treatment of disease: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.... Agent: Validus Genetics

20120094971 - Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.... Agent: Repligen Corporation

20120094972 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20120094973 - Catechol-based derivatives for treating or preventing diabetics: The present invention provides a catechol-based derivative and a pharmaceutical acceptable salt therefrom and a solvate therefrom. A pharmaceutical composition for preventing or treating diabetes and ischemia, comprising a catechol-based derivative of formula (I) and at least one selected from the group consisting of a pharmaceutical excipient, a diluent and... Agent: National Taiwan University

20120094976 - New chemical compounds: e

20120094975 - Pyrido [5, 4-d] pyrimidines as cell proliferation inhibitors: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X1, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.... Agent: Boehringer Ingelheim International Gmbh

20120094974 - Smoothened receptor modulators: The present invention relates, in general, to the Smoothened receptor and, in particular, to a method of modulating Smoothened receptor activity and to compounds and compositions suitable for use in such a method.... Agent:

20120094977 - Compositions and methods for the treatment of disease associated with trp-p8 expression: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating... Agent: Dendreon Corporation

20120094978 - Ocular allergy treatments: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.... Agent:

20120094979 - Thiazole or thiadizaloe derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists: Thiazole or thiadizaloe derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.... Agent: Glaxo Wellcome House

20120094981 - Anthelmintic agents and their use: This invention is directed to compounds of the formula (I) and salts therefore that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds of this invention, pharmaceutical compositions and kits comprising the compounds... Agent:

20120094980 - Pyridyl inhibitors of hedgehog signalling: i

20120094982 - 1,4-benzodiazepinone compounds and their use in treating cancer: The invention provides a family of 1,4-benzodiazepinone compounds and methods for their use as therapeutic agents in treating cancer. Pharmaceutical compositions and methods of making the 1,4-benzodiazepinone compounds are provided.... Agent: The Regents Of The University Of Michigan

20120094983 - Acyclic ikur inhibitors: e

20120094984 - Fused aminodihydrothiazine derivatives: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3... Agent: Eisai R&d Management Co., Ltd.

20120094985 - Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments:

20120094986 - Anticancer deriviatives, preparation thereof, and therapeutic use thereof: The invention relates to nicotinamide derivatives which can be used as anticancer drugs.... Agent: Sanofi-aventis

20120094987 - Substituted pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines and pyrido [3', 2': 4, 5] furo [3, 2-d] pyrimidines used as inhibitors of the pde-4 and/or the release of tnf-alpha: The invention relates to compounds of general formula (I); 1a, 1b, 1c and 1d. The invention also relates to a method for the production thereof, pharmaceutical preparations containing said compounds and/or physiologically compatible salts thereof which can be produced therefrom and/or solvates thereof, and to the pharmaceutical use of said... Agent:

20120094988 - Enhancement of plant growth: Treatment with N-(2-phenylethyl)succinamic acid or its salts protects against inhibition of growth by a neonicotinoid compound applied as a seed treatment or applied directly on or near the root zone of the seedling.... Agent:

20120094989 - 5-ht receptor modulating compounds: The present invention relates to compounds having 5-hydroxytryptamine receptor modulating activity, in particular compounds having an acidic moiety held distant from the 5-HT pharmacophore by a rigid linker group, to compositions containing such compounds and methods of treatment using them. Such compounds have an increased affinity for the 5-HT receptor... Agent: Serodus As

20120094991 - 1, 4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions: The present invention includes compositions and methods for inhibiting kinase activity to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such as ischemic stroke comprising the step of providing the subject with a therapeutically affective amount of 1,4-benzoxazine compounds and derivatives thereof.... Agent: Board Of Regents ,the University Of Texas System

20120094993 - N-pyridin-3-yl or n-pyrazin-2-yl carboxamides: wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof. The present invention also relates to the manufacture of such compounds or their pharmaceutically acceptable salts, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can... Agent:

20120094990 - Phenylacetic acid compound: e

20120094992 - Poly (adp-ribose) polymerase (parp) inhibitors:

20120094994 - Functionalized amino acids and absorbable polymers therefrom:

20120094995 - 2-aza-bicyclo[2.2.1]heptane compounds and uses thereof: This invention relates to 2-aza-bicyclo[2.2.1]heptane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GlyT1) and for the treatment of psychosis, cognitive disorders, bipolar disorders,... Agent: Astrazeneca Ab

20120094996 - Imidazo [2, 1-b] [1, 3, 4] thiadiazole derivatives: There is provided compounds of formula (I): wherein R1, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K)... Agent: Centro Nacional De Investigaciones Oncologicas (cnio)

20120094997 - Substituted hydroxamic acids and uses thereof: wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases... Agent: Millennium Pharmaceuticals, Inc.

20120094998 - Oligomer-protein tyrosine kinase inhibitor conjugates: The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water soluble, non peptidic oligomer.... Agent: Nektar Therapeutics

20120095000 - Compounds for activating tgf-beta signaling: Compositions and methods for treatment and prevention of disorders and conditions characterized by reduced TGF-β signaling are described.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120094999 - Egfr inhibitors and methods of treating disorders: The present invention relates to novel pyrimidine, pyrrolo-pyrimidine, pyrrolo-pyridine, pyridine, purine and triazine compounds which are able to modulate epidermal growth factor receptor (EGFR), including Her-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.... Agent: Dana-farber Cancer Institute, Inc.

20120095001 - Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones: The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck Sharp & Dohme Corp.

20120095002 - Isoxazole-5-carboxamide derivatives: The present invention relates to isoxazole-5-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-5-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and... Agent: N.v. Organon

20120095003 - Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.... Agent: Xenoport, Inc.

20120095004 - Sphingosine kinase inhibitors: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.... Agent: Apogee Biotechnology Corporation

20120095005 - Fused bicyclic pyrazole derivatives as kinase inhibitors: A series of substituted pyrazolo[1,5-α][1,3,5]triazine and pyrazolo[1,5-αj-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).... Agent: Ucb Pharma S.a.

20120095006 - Treatment of pulmonary hypertension: This invention relates to the use of certain cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.... Agent: Pfizer Inc.

20120095008 - Composition and methods for the treatment of wounds: The present invention is directed to a wound composition comprising an effective amount of phenytoin and an effective amount of vitamin C. The present invention is further directed to a method of treating a wound in a patient comprising administering an effective amount of phenytoin and an effective amount of... Agent:

20120095009 - Synthesis and anti-proliferative effect of benzimidazole derivatives: e

20120095010 - Tricyclic delta-opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent:

20120095007 - Carbamoyloxy arylalkan arylpiperazine analgesics: There is provided a novel carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain (i.e., acute or chronic pain, neuropathic pain, inflammatory pain, diabetic pain, postherpetic... Agent: Sk Holdings Co. Ltd.

20120095011 - Novel compounds: e

20120095012 - Toluidine sulfonamides and their use: The present invention provides compounds of formula (I), wherein R1 is a monocyclic 5- or 6-membered heteroaryl; R4 is phenyl or monocyclic 5- or 6-membered heteroaryl; and the other substituents as defined in the claims, that inhibit cell and cell division and that inhibit the activation of Hypoxia Inducible Factor... Agent: Elara Pharmaceuticals Gmbh

20120095013 - Use of kmup-3 for myocardial infarction: A pharmaceutical composition for improving a cardiac function is provided. The pharmaceutical composition comprises an effective amount of an active component being one of a KMUP-3 compound and a salt thereof.... Agent: Kaohsiung Medical University

20120095014 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Incorporated

20120095015 - Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated... Agent:

20120095016 - Therapeutic 5,6,5-tricyclic analogs: The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABAA receptor and negatively modulating the α5 subtype of GABAA, and use of the compound of formula I in the manufacture of a medicament for... Agent: Helicon Therapeutics, Inc.

20120095017 - Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Bristol-myers Squibb Company

20120095018 - 5-ht1a receptor subtype agonist: i

20120095019 - Methods and formulations of treating thrombosis with betrixaban and a p-glycoprotein inhibitor: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.... Agent:

20120095020 - Cathepsin s inhibitor compounds: or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The present invention further provides methods for treating abdominal aortic aneurysm, plaque instability, atherosclerosis, or autoimmune disorders... Agent: Eli Lilly And Company

20120095022 - Derivatives of 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-ones, method for preparation thereof and therapeutic uses thereof:

20120095021 - Synthsis of new benzothiazole derivatives as potential anti-tubercular agents: The present disclosure provides a compound of general formula A useful as potential anti-tubercular agents.... Agent: Council Of Scientific And Industrial Research

20120095023 - Novel heterocyclic compounds as pesticides: The present application relates to novel amides and thioamides, to processes for preparation thereof and to the use thereof for controlling animal pests, in particular arthropods and especially insects.... Agent: Bayer Cropscience Ag

20120095024 - Toluidine sulfonamides and their use: The present invention provides novel compounds that inhibit cell proliferation and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)-mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or... Agent: European Molecular Biology Laboratory (embl)

20120095025 - Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators: This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines useful as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. Formula (I).... Agent: Neurosearch A/s

20120095026 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Pharmacyclics, Inc.

20120095027 - Synthesis and anti-proliferative effect of benzimidazole derivatives: s

20120095028 - 3-oxa-7-azabicyclo[3.3.1]nonanes: Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.... Agent: Pfizer Inc.

20120095030 - Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors: Methods of using specific microRNA to identify subjects with non-small cell lung cancer likely or unlikely to respond to treatment with tyrosine kinase inhibitors such as erlotinib, sunitinib, or vandetanib; methods of treating subjects based on identification of said subjects as likely to respond to treatment with tyrosine kinase inhibitors;... Agent: The Translational Genomics Research Institute

20120095029 - Ipp complex as marker for erlotinib treatment: The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients.... Agent: Hoffmann-la Roche Inc.

20120095031 - Cyclopropane compound: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like,... Agent: Eisai R&d Management Co., Ltd.

20120095032 - Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same: The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates... Agent: Sanford-burnham Medical Research Institute

20120095033 - Selective glycosidase inhibitors and uses thereof: The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.... Agent: Simon Fraser University

20120095034 - Piperidine derivatives useful as orexin receptor antagonists: This invention relates to imidazo[1,2-a]pyridin-2-ylmethyl substituted piperidine derivatives of formula (I) and their use as pharmaceuticals, in the treatment of obesity and diabetes.... Agent:

20120095035 - Crystals of prasugrel hydrobromate: The present application discloses crystals of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.... Agent: Shanghai Institute Of Pharmaceutical Industry

20120095036 - Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators: wherein R1, R2, R3, R4, Y, A1, A2, A3, A4, X1, X2, X3 and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said... Agent:

20120095037 - Synthesis and anti-proliferative effect of benzimidazole derivatives: e

20120095038 - Synthesis and anti-proliferative effect of benzimidazole derivatives:

20120095039 - Heterocyclic compounds with affinity to muscarinic receptors: The present invention relates to heterocyclic compounds of formula (I) having affinity to muscarinic receptors, a pharmaceutical composition containing the compounds, as well as the use of the compounds for the preparation of a medicament for treating, alleviating or preventing muscarinic receptor mediated diseases and conditions.... Agent: Solvay Pharmaceuticals B.v.

20120095040 - Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof: The invention relates to compounds of the general formula (I) where: R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, or NR8R9 group; m, n, o and p independently are a number from 0 to 3; A is a covalent bond, an oxygen atom, a... Agent: Sanofi

20120095041 - Reversible nondepolarizing neuromuscular blockade agents and methods for their use: The invention provides neuromuscular blockade agents of the non-depolarizing type with few if any circulatory effects. Compounds of the invention include bis(isoquinolylalkanol) diesters of fumaric, maleic, succinic, and acetylenedicarboxylic acids; compositions suitable for parenteral administration of these compounds as a surgical adjunct to anesthesia, and methods of preparation of the... Agent: Cornell University

20120095042 - Organic compounds having cooling properties: e

20120095043 - Triglyceride-lowering agent and hyperinsulinism-ameliorating agent:

20120095045 - Injectable anticancer composition for local administration containing hydroxychloroquine: The present invention relates to an injectable anticancer composition for local administration comprising hydroxychloroquine. The anticancer composition shows an IC50 value against sarcoma-180 cells, which is about 10 times lower than cisplatin, as determined by the MTT assay in vitro, suggesting that the anticancer composition has an excellent cytotoxic effect.... Agent:

20120095044 - Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.... Agent: Sanford-burnham Medical Research Institute California

20120095046 - Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both... Agent: The University Of Edinburgh

20120095047 - Novel heteropyrrole analogs acting on cannabinoid receptors: Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or the CB2 cannabinoid receptors. One aspect discloses hetero pyrrole analogs acting as antagonists for the CB1 and/or the CB2 receptors. Another aspect discloses hetero pyrrole analogs having selectivity for... Agent: University Of Connecticut

20120095048 - Allosteric binding compounds: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.... Agent: Aarhus Universitet

20120095049 - Nociceptin analogs: e

20120095050 - Stabilized and preserved ketotifen ophthalmic compositions: Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.... Agent:

20120095051 - Curcumin analogues as zinc chelators and their uses: wherein α, β, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method... Agent:

20120095052 - Par-1 antagonism in fed or antacid-dosed patients: e

20120095053 - Aminotetrahydroindazoloacetic acids: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I... Agent:

20120095055 - Hexahydrocyclopentyl[f]indazole 5-hydroxymethyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators: The present invention encompasses compounds of Formula (I): or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck Sharp & Dohme, Corp.

20120095054 - Polymorphs of esomeprazole salts: The present invention relates to a high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention further provides an improved and commercially viable process for preparation of high assayed esomeprazole magnesium dihydrate substantially free of its trihydrate form. The present invention also provides an improved process... Agent: Hetero Drugs Limited

20120095056 - 2,5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators: This invention relates to novel tetrazole derivatives of formula (I), which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system... Agent: Neurosearch A/s

20120095057 - Pyrazole compound: wherein R1 is a substituent, R2 is (i) a hydrogen atom, (ii) a C1-6 alkyl group optionally having a halogen atom or (iii) a cyano group, R3 is (i) a hydrogen atom, (ii) a halogen atom, (iii) a cyano group, (iv) a C1-6 alkyl group optionally having a halogen atom... Agent: Takeda Pharmaceutical Company Limited

20120095059 - Compositions and methods for treating type ii diabetes and related disorders: The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable... Agent:

20120095058 - Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses: The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that... Agent:

20120095060 - Methods and compositions of mitogen-activated protein kinase (mapk) pathway inhibitors for treating pulmonary fibrosis: Methods and compositions of inhibitors of MAPK kinases 1 and 2 (MEK1 and MEK2, or together, MEK1/2), such as ARRY142886, and their use in inhibiting MEK1/2 kinase activity in mammals for the treatment and/or reversal of the symptoms of pulmonary fibrosis. MEK1/2 inhibitors can selectively inhibit the MAPK/ERK pathway in... Agent:

20120095061 - Fluorinated derivatives of deferiprone: The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron... Agent: Apotex Technologies Inc.

20120095062 - Tricyclic compounds, compositions, and methods: e

20120095063 - Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative... Agent:

20120095064 - (pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds: wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br,... Agent:

20120095065 - Macrocyclic compounds and methods of treatment: The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.... Agent: University Of Florida Research Foundation, Inc.

20120095066 - Composition comprising an epothilone and methods for producing a composition comprising an epothilone: The present invention concerns methods for the production of pharmaceutical formulations of Epothilones suitable for being administered parenterally, such as intravenously.... Agent:

20120095067 - Pharmaceutical composition containing carboxylosartan and a production method therefor: Disclosed is a pharmaceutical composition containing losartan carboxylic acid and a preparing method thereof. The pharmaceutical composition has the improved dissolution speed and dissolution rate, and the reduced variation in dissolution depending on the pH of a medium.... Agent: Jin Yang Pharm. Co., Ltd.

20120095068 - Imidazolidine-2,4-dione derivatives and use thereof as a medicament: The subject matter of the present application is novel imidazolidine-2,4-dione derivatives of general formula (I) in which R1, R2, R3 and X are variables. These products have an anti-proliferative activity. They are particularly advantageous for treating pathological conditions and diseases associated with abnormal cell proliferation, such as cancers. The invention... Agent: Ipsen Pharma S.a.s.

20120095069 - Pharmaceutical oral telmisartan solution: A pharmaceutical solution, preferably a drinkable pharmaceutical solution of the active substance telmisartan is described, having a pH above 10 and additionally containing one or more sugar alcohols added to improve the flavour and shelf life, wherein the sugar alcohols or the pharmaceutical solution have a maximum content of 1000... Agent: Boehringer Ingelheim Vetmedica Gmbh

20120095070 - Prevention and treatment of sarcopenia: The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.... Agent: Psioxus Therapeutics Limited

20120095071 - 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom: Substantially pure 3-(3-indolyl)propionic acid free acid is synthesized by converting the free acid to 3-(3-indolyl)propionic acid calcium salt (3-IPA calcium), precipitating and washing, and then reconverting the 3-IPA calcium to the free acid. 3-IPA calcium is suitable for use in pharmaceutical compositions in tablet and sustained-release dosage forms. 3-IPA calcium... Agent: Intellect Neurosciences Inc.

20120095072 - Crystalline sodium atorvastatin: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.... Agent: Arrow International Limited

20120095073 - Ion channel modulating activity ii: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion... Agent: Cardiome Pharma Corp.

20120095087 - Enhanced products by sustainable processes for medicinal use: A process for producing a composition with bioactive and/or bioavailable Cannabis-derived cannabinoids known to be effective for CB1 and/or CB2 modulation, and a plurality of indications for patients in need. Using a heat cycle process to combine cannabinoids, including but not limited to THC and CBD with flax seed oil... Agent:

20120095088 - Medicinal cannabis uniform in food: The invention is a product and a process wherein cannabinoids such as Medicinal Δ9-THC and/or other substances associated with medicinal cannabis, including yet not necessarily limited to cannbidiols, cannabigerol are contained or processed into foodstuffs or medicinal compounds in controlled ways and with specific characteristics. First a medicinal substance with... Agent:

20120095089 - Schweinfurthins and uses thereof: Disclosed is a method for preventing or treating an undesirable condition in a subject carrying cells homozygous null for the neurofibromatosis type 1 gene or subjects that are haploinsufficient for the neurofibromatosis type 1 gene, the method comprising administering to a subject in need thereof an effective amount of a... Agent: The United States Of America,as Represented By The Secretary,department Of Health And Human Services

20120095090 - Novel composition and method for stabilizing the same: Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.... Agent: Sucampo Ag

20120095091 - Antiepileptic, hypocholesterolemic and neuroprotective compound: its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for its use in the prevention of: neurodegenerative diseases, cognitive deterioration, diseases... Agent: Neuron Biopharma S.a

20120095092 - Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same: s

20120095093 - Antifungal compounds: Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful... Agent:

20120095094 - Process for cosmetic treatment using ferutinine from ferula genus plants: The invention relates to a process for cosmetic treatment, including the reduction of superficial and deep wrinkles, using ferutinine from Ferula spp extracts.... Agent: Indena S.p.a.

20120095095 - Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs: The present invention provides methods of limiting cell death resulting from hypoxic-ischemia comprising, administering an omega-3 lipid-based emulsion after a hypoxic-ischemia insult. The omega-3 lipid-based emulsion preferably comprises at least 20% omega-3 oil, by weight, and wherein the omega-3 oil comprises at least 20% omega-3 triglycerides and/or diglycerides, and wherein... Agent: The Trustees Of Columbia University In The City Of New York

20120095096 - 2-oxamide inhibitors of phospholipase a2 activity and cellular arachidonate release based on dipeptides and pseudopeptides: The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA2 and GVIA 1PLA2) and one human secretory phospholipase A2 (GVsPLA2) were evaluated. Derivatives containing a free carboxyl group are selective GIVA cPLA2 inhibitors. A... Agent: The Regents Of The University Of California

20120095097 - Ophthalmic composition: Disclosed is an ophthalmic composition containing (A) not less than 50,000 units/100 mL of vitamin A, (B) not less than 0.4 W/V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.... Agent:

20120095098 - Bioavailability enhancement delivery system: A composition for increasing the bioavailability of drugs in humans and animals comprising a microemulsion further comprising a first emulsifier, a second emulsifier, and an oil wherein the emulsifiers have individual HLB values of between about 10 and about 30, are in a ratio ranging from about 1:1 to about... Agent:

20120095099 - Trans carotenoids, their synthesis, formulation and uses: The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.... Agent: Diffusion Pharmaceuticals LLC

20120095100 - Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility: The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility.... Agent: Merck Serono S.p.a.

20120095101 - Aqueous intraocular penetration-promoting eye drop: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or... Agent:

20120095102 - Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof: The present invention relates to salts of 3-pentylphenylacetic acid and their pharmaceutical uses. Particular aspects of the invention relate to the use of those salts in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention and treatment of (i) blood disorders, (ii) renal disorders and... Agent:

20120095103 - Compounds for treating proliferative disorders: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.... Agent: Synta Pharmaceuticals Corp.

20120095104 - Use of vasoconstrictors: There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed.... Agent:

20120095105 - Inhibitors of cognitive decline: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods... Agent: Cognition Therapeutics, Inc.

20120095107 - Methods for treatment of cardiovascular disorders and diseases: Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.... Agent: Technion Research And Development Foundation Ltd.

20120095106 - Preparation of chiral amides and amines: This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides... Agent: Sunovion Pharmaceuticals Inc.

20120095108 - Composition containing microbial zeaxanthin and preparation thereof: The present invention relates to a composition for prevention and/or treatment of human skin alteration or disease comprising an extract of marine bacteria selected from Flavobacteriaceae, wherein the extract contains an effective amount of zeaxanthin. The present invention also relates to a method for preparing the above composition, comprising: (a)... Agent: Vigenent Inc.

20120095109 - Film forming, silicone containing compositions: The invention relates to silicone containing compositions able to form adhesive films on substrates, which typically comprises a curable silicone composition comprising components (a), (d) and at least one of (b) or (c): a. a polyorganosiloxane resin, composed of M and Q units having at least 3 alkenyl groups per... Agent:

20120095110 - Branched polymer dispersants: The present invention relates to the use of a branched addition copolymer as a dispersant in a gaseous, liquid or solid formulation in a range of applications and to the copolymers per se wherein the copolymer is obtainable by an addition polymerisation process, wherein said copolymer comprises: at least two... Agent: Unilever PLC

20120095111 - Branched polymer dispersants: The present invention relates to the use of a branched addition copolymer as a dispersant in a gaseous, liquid or solid formulation in a range of applications and branched addition copolymers suitable for same wherein the copolymer is obtainable by an addition polymerisation process, wherein said copolymer comprises: at least... Agent: Unilever PLC

20120095112 - Branched polymer dispersants: The present invention relates to the use of a branched addition copolymer as a dispersant in a gaseous, liquid or solid formulation in a range of applications and to the copolymers per se wherein the copolymer is obtainable by an addition polymerisation process, wherein said copolymer comprises: at least two... Agent: Unilever House

20120095113 - Refreshing cream foundation in gel form: The present invention is directed to a cosmetic composition includes (a) at least one compound selected from a sugar silicone surfactant, a gelling agent, a polyamine and a hyperbranched polyol; and (b) at least one polar modified polymer.... Agent: L'oreal S.a.

20120095115 - Ester mixtures and compositions comprising such ester mixtures: The invention is directed to a mixture of esters according to the general formula (I), R1—C(═O)—O—R2, wherein R1 is an alkyl moiety with 7 to 9 carbon atoms and wherein R2 is a an alkyl moiety with 8 to 10 carbon atoms, wherein the mixture comprises 5 to 60 weight-%... Agent:

20120095114 - Functionalized biodegradable triclosan monomers and oligomers for controlled release: This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.... Agent: Bezwada Biomedical, LLC

20120095117 - Galectin-3 nssnp marker for cancer: A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H64 and/or P98 allele of... Agent: Wayne State University

20120095116 - Probe set for identification of nucleotide mutation, and method for identification of nucleotide mutation: A probe set comprising a detection probe and a counter probe, wherein the detection probe comprises an oligonucleotide which comprises a nucleotide sequence containing the mutation site on the target nucleic acid and also containing a nucleotide of interest in the mutation site or a nucleotide sequence complementary to the... Agent: Vertex Pharmaceuticals Incorporated

  
04/12/2012 > 137 patent applications in 103 patent subcategories. category listing, related patent applications

20120088714 - System for storage and subsequent handling of botulinum toxin: A system and method for storage of botulinum toxin containing pharmaceutical compositions is herein disclosed. Particular aspects of the instant disclosure relate to vials having preferred internal geometries that provide optimized lyophilization, vacuum drying, storage, reconstitution and extraction of a botulinum toxin-containing pharmaceutical composition.... Agent: Allergan, Inc.

20120088713 - Tnf inhibitor formulation for use in implantable infusion devices: A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the... Agent: Medtronic Inc.

20120088715 - Mutated antithrombins, a process for preparing the same and their use as drugs: f

20120088716 - Polypeptide protracting tags: Method for increasing half-life of compounds in plasma and novel derivatives of such compounds.... Agent: Novo Nordisk A/s

20120088717 - Method for treating fungal infection with antifungal bifunctional molecules: The present invention is directed to a method of treating a fungal infection with a fusion peptide that includes a fungal targeting agent and a channel-forming domain consisting essentially of amino acids 451-626 of colicin Ia. The fungal targeting agent can be a pheromone, such as an alpha-mating pheromone. The... Agent: Pheromonicin Biotech, Ltd.

20120088718 - Hcv-derived polypeptides and uses thereof: The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and... Agent: Institut Pasteur

20120088719 - Mosquitocidal xenorhabdus, lipopeptide and methods: Provided is a bacterial strain which produces a family of mosquitocidal toxins, Xenorhabdus MT, on deposit with the American Type Culture Collection, PTA-6826, insecticidal compositions comprising the mosquitocidal toxin(s) produced by Xenorhabdus MT, a mosquitocidal toxin preparation prepared from spent culture medium, whole culture or cells or a mixture thereof,... Agent:

20120088720 - Inhibitors of protein tyrosine phosphatases: Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these... Agent: Indiana University Research & Technology Corporati

20120088721 - Cartilage repair: This invention relates to compositions, methods of preparation thereof, and use thereof for cartilage repair.... Agent: Genzyme Corporation

20120088722 - Compositions and methods for inhibition of mmp:mmp-substrate interactions: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent... Agent:

20120088723 - Selective ep4 receptor agonistic substance for treatment of cancer: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically... Agent: Raqualia Pharma Inc.

20120088724 - Human growth hormone formulations: Formulations containing complexed human growth hormone crystals are described. Also described are needleless injection systems for crystalline proteins.... Agent: Althea Technologies, Inc.

20120088725 - 5-cnac as oral delivery agent for parathyroid hormone fragments: Pharmaceutical compositions for the effective oral delivery of a parathyroid hormone, PTH, as well as methods for administration of the compositions are provided. Additionally, methods for stimulating new bone formation and treating and/or preventing osteoporosis are also provided.... Agent:

20120088726 - Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations: Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal,... Agent: Alfa Wassermann, S.p.a.

20120088727 - Rspondins as modulators of angiogenesis and vasculogenesis: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2... Agent: Deutsches Krebsforschungszentrun Stiftung Des Offentlicen Rechts

20120088728 - Use of c1 inhibitor for the prevention of ischemia-reperfusion injury: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic... Agent: Pharming Intellectual Property B.v.

20120088729 - Non-glycosylated transferrin expressed in monocots: Disclosed are compositions and methods of making non-glycosylated transferrin protein in transgenic monocot plants.... Agent: Ventria Bioscience

20120088730 - Use of angiotensin converting enzyme (ace) domain specific inhibitors to inhibit or enhance cytokine production and alter immune response: The present invention relates to the discovery that the two ACE domains can have very different effects on cytokine expression. In one embodiment, the present invention provides a method of regulating and/or treating a condition in a subject by administering a therapeutically effective dosage of site specific ACE inhibitor. In... Agent: Cedars-sinai Medical Center

20120088731 - Method for treating parkinson's disease through regulating vdac1 protein: The present invention provides a method for curing Parkinson's disease through regulating VDAC1 (voltage-dependent anion channel 1) protein. Specifically, the present invention provides a pharmaceutical composition for curing PD comprising a VDAC1 protein regulator. The VDAC1 protein regulators comprise an inhibitor of VDAC1 mRNA production, an inhibitor of mitochondrial permeability... Agent: Snu R&db Foundation

20120088732 - Therapeutic composition comprising a botulinum neurotoxin: A pharmaceutical preparation comprising one of the botulinum neurotoxins from Clostridium botulinum of types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, wherein the neurotoxin or the mixture of neurotoxins is free of the complexing proteins which naturally form the... Agent: Merz Pharma Gmbh & Co. Kgaa

20120088733 - Novel use of antimicrobial peptides in regeneration of skin cells: The antimicrobial peptides exhibit inhibitory activity against antibiotic-resistant strains, and their antimicrobial activity is maintained without loss of structural stability even under a high salt condition. Also, being proven to promote the migration and regeneration of skin cells in mice as well as in vitro, the antimicrobial peptides may be... Agent: Korea Advanced Institute Of Science And Technology

20120088734 - Cyclosporin analogs: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.... Agent: Allergan, Inc.

20120088813 - Anti viral therapy: The present invention provides a method of identifying host cell molecules which may be modulated to inhibit viral replication and method of testing antiviral compounds. In addition, the invention provides compositions, methods and medicaments for treating viral infections and/or diseases or conditions caused or contributed to by viruses.... Agent:

20120088812 - Compositions for promoting epigenetic dna demethylation and methods of use therefore: The invention features compositions and methods for modulating the expression of Gadd45 and the use of such compositions and methods as neuroprotectants, to enhance neurogenesis, and for the treatment of mood disorders.... Agent: The Johns Hopkins University

20120088816 - Head-and-neck tumor proliferation inhibitor: It is to provide a novel head-and-neck tumor proliferation inhibitor, head-and-neck tumor metastasis inhibitor and pharmaceutical composition for treating a head-and-neck tumor. The present invention is characterized by using an inhibitory substance of a microRNA whose expression increases in a head-and-neck tumor and/or a promoting substance of a microRNA whose... Agent: Keio University

20120088811 - Method for the treatment of acute myeloid leukemia: The invention is in the field of molecular medicine and provides methods for the treatment of acute myeloid leukemia. These methods are based on the observation that microRNA-9 and microRNA-9* are involved in the pathogenesis of the disease in that the overexpression of microRNA-9/9* block myeloid differentiation in vitro. More... Agent: Erasmus University Medical Center Rotterdam

20120088814 - Methods of modulating an immune response to a viral infection: Disclosed herein are methods for treating respiratory disorders via administration of antisense compounds targeting IL-4Rα. Provided herein, for example, are compositions and methods of modulating immune responses to a viral infection in a subject. Also provided, for example, are compositions and methods for managing, treating, ameliorating, preventing and/or delaying the... Agent: Isis Pharmaceuticals, Inc.

20120088815 - Modified oligonucleotide and its preparation and application: The present invention relates to a modified oligonucleotide, its preparation and application. The invention enables stabilizing the oligonucleotide by introducing a relatively small amount of modified nucleotide at specific UA/UA and/or CA/UG and/or UG/CA site of the oligonucleotide, therefore to decrease the modification-related cytotoxicity and compromising effects on the biological... Agent: Biomics Biotechnologies Co. Ltd

20120088817 - Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Antiviral gene, in particular, by targeting natural antisense polynucleotides of an Antiviral gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent: Opko Curna, LLC

20120088818 - Conformation-selective nucleic acid inhibitors of ampa glutamate receptors: The present invention relates to novel nucleic acid ligands or aptamers that demonstrate potent and selective inhibition of the open-channel conformation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors.... Agent: The Research Foundation Of State University Of New York

20120088819 - Method for enhancing expression of recombinant protein: The present invention provides methods for enhancing protein expression from an RNA viral vector and RNA viral vectors with enhanced protein expression capacity. The present inventors successfully increased the level of protein expression significantly by expressing the proteins fused with an AB5B protein from RNA viral vectors. Effective gene therapy,... Agent:

20120088820 - Pharmaceutical composition for treating and preventing diseases related to joints and connective tissue: The present invention relates to a pharmaceutical composition for preventing and treating joint-related disease and connective tissue-related disease, the composition comprising two or more selected from the group consisting of polyol, amino acid, ornithine, nucleic acid and vitamin C. The pharmaceutical composition prevents and treats new arthritis, joint damage and... Agent:

20120088735 - One-step processing of hydrogels for mechanically robust and chemically desired features: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue... Agent: The Board Of Regents, The University Of Texas System

20120088736 - [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto: The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Portola Pharmaceuticals, Inc.

20120088738 - Inhibitors of fatty acid amide hydrolase: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically... Agent: Infinity Pharmaceuticals ,inc

20120088737 - Novel acyl guanidine derivatives: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.... Agent: Ajinomoto Co., Inc

20120088739 - Method for treating meibomian gland disease: A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of... Agent: The University Of Miami

20120088742 - Acetylsalicylic acid salts: Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.... Agent: Tetra, Sia

20120088741 - Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase: Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy... Agent:

20120088740 - Co-crystals and pharmaceutical compositions comprising the same: The invention relates to compositions and co-crystals each comprising VX-950 and a co-crystal former selected from the group consisting of salicylic acid, 4-amino salicylic acid, and oxalic acid. Also within the scope of this invention are methods of making and using the same.... Agent: Vertex Pharmaceuticals Incorporated

20120088743 - Combinations comprising antimuscarinic agents and pde4 inhibitors: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniablcyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent:

20120088744 - Compositions for treating cmt and related disorders: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.... Agent: Pharnext

20120088745 - Chemically modified small molecules: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a... Agent:

20120088746 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and... Agent: Renovis, Inc.

20120088748 - Heterocyclic compounds: m

20120088749 - S1p receptor modulating compounds and use thereof: The present invention relates to amides that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including... Agent: Amgen, Inc.

20120088747 - Sulfonamide containing compounds and uses thereof: Compounds, compositions and methods for treating GHS-R mediated disorders are described herein.... Agent:

20120088750 - Antibacterial compounds: m

20120088752 - Hedgehog pathway antagonists and therapeutic applications thereof: Heterocyclic compounds that modulate the hedgehog signaling pathway, pharmaceutical composition thereof and their therapeutic applications.... Agent: Siena Biotech S.p.a.

20120088751 - Pharmaceutical compounds: t

20120088753 - Pyrrolopyrimidines and used as kinase inhibitors: The invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is —NR7(CO)R11; R2 is aryl, heteroaryl, fused aryl-C3-6-heterocycloalkyl or fused heteroaryl-C3-6-heterocycloalkyl, each of which is optionally substituted; each R7 is selected from hydrogen, C1-6-alkyl and C3-7-cycloalkyl, wherein said C1-6-alkyl is optionally... Agent: Medical Research Council Technology

20120088754 - Sulfonyl-derivatives as novel inhibitors of histone deacetylase: e

20120088758 - Five-membered heterocycles useful as serine protease inhibitors: or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation... Agent: Bristol-myers Squibb Company

20120088756 - Methods for regulating neurotransmitter systems by inducing counteradaptations: The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a neurotransmitter includes the step of repeatedly administering a ligand for a receptor in the neurotransmitter system, with a ratio of administration half-life to... Agent:

20120088757 - Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of... Agent: The Regents Of The University Of Michigan

20120088755 - Novel compounds: wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic... Agent: Boehringer Ingelheim International Gmbh

20120088759 - Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists: The present invention relates to thiazolidin-4-one and [1,3]-thiazinan-4-one compounds of formula (I) wherein X, Y, R3 and R4 are as described in the description, or pharmaceutically acceptable salts thereof, for the prevention or treatment of diseases related to the orexin system. The present invention also relates to novel thiazolidin-4-one compounds... Agent:

20120088760 - Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient: e

20120088761 - Aminoacyl prodrug derivatives and medicaments for the treatment of thromboembolitic disorders: The present application relates to prodrug derivatives of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of thromboembolic disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120088762 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Onyx Therapeutics, Inc.

20120088763 - Triazolopyridine derivatives and their therapeutic use: Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of inter alia, diseases of the respiratory tract wherein; R1 is C1-C6 alkyl, C3-C6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical... Agent: Chiesi Farmaceutici S.p.a.

20120088766 - Fused heterocyclic compounds and their uses: The present application relates to therapeutic organic compounds, compositions comprising an effective amount of a therapeutic organic compound; and methods for treating and preventing disease comprising administering and effective amount of a therapeutic organic compound to a subject in need thereof.... Agent: Dana-farber Cancer Institute, Inc.

20120088764 - Phosphoinositide 3-kinase inhibitors with a zinc binding moiety: The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase... Agent: Curis, Inc.

20120088765 - Purine derivative and antitumor agent using same: Disclosed are: a novel purine derivative, a composition thereof, a method for treating tumor using the purine derivative, and an antitumor agent using the purine derivative. Specifically disclosed is a compound represented by formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, or a prodrug thereof.... Agent: Zenyaku Kogyo Kabushikikaisha

20120088767 - Benzimidazole derivatives as pi3 kinase inhibitors: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kβ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of... Agent:

20120088768 - Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors: Pinane-substituted pyrimidinediamine derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20120088769 - Salts of arylsulfonamide ccr3 antagonists: Provided herein are arylsulfonamide salts, e.g., a salt of a compound of Formula I, which are useful for modulating CCR3 activity, and their pharmaceutical compositions. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.... Agent: Axikin Pharmaceuticals, Inc.

20120088770 - Alpha helix mimetics and methods relating thereto: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases,... Agent: Prism Biolab Corporation

20120088772 - Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder: The present invention is to provide a therapeutic agent for attention deficit/hyperactivity disorder having a novel mechanism of action which is different from conventional psychostimulants. The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder, comprising a BEC1 potassium channel inhibitor... Agent: Astellas Pharma Inc.

20120088771 - Tissue-nonspecific alkaline phosphatase (tnap): a therapeutic target for arterial calcification: This invention relates generally to the field of mineralization, and specifically to the role of TNAP in regulating the levels of extracellular inorganic pyrophosphate. The invention provides methods for modulating the activity of TNAP activity; methods for screening for modulators of TNAP activity; modulators of TNAP activity; and methods for... Agent: Sanford-burnham Medical Research Institute California

20120088774 - Active pharmaceutical ingredient adsorbed on solid support: The present invention belongs to the field of pharmaceutical industry and relates to dosage forms comprising active pharmaceutical ingredients (API) such as tadalafil, simvastatin, fenofibrate and lovastatin that are practically insoluble in water, adsorbed on a carrier. Furthermore it relates to an adsorbate comprising API being practically insoluble in water... Agent: Lek Pharmaceuticals D.d.

20120088773 - Circadian rhythm modulation: A method and composition is herein described to modulate the circadian rhythm to effect summer metabolism and the metabolic syndrome. The method entails the once daily, timed ingestion of a dopamine precursor or a dopamine agonist, receptor primed with caffeine, and vitamin D3.... Agent:

20120088775 - Pyrazolo-[1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof: The present invention provides new pyrazolo-[1,5-a]-pyrimidone derivates and pharmaceutical compositions comprising said compounds and one or more pharmaceutically acceptable carriers or diluents. The uses of the compounds for the manufacture of potassium channel openers, anti-epilepsy medicaments, anti-anxiety medicaments and analgesic medicaments are also provided in the present invention.... Agent: Hebei Medical University

20120088776 - Treatment of mammalian disorders mediated by alpha-anhydrase isoforms: The present invention pertains to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof, or 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof, for the treatment of disorders mediated by alpha-carbonic anhydrase isoforms selected from intraocular hypertension (glaucoma), epilepsy, Lennox-Gastaut syndrome, altitude sickness, headaches, neurological disorders and obesity.... Agent:

20120088777 - 5-ht1a receptor subtype agonist: e

20120088778 - Azole derivatives and fused bicyclic azole derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Transtech Pharma, Inc.

20120088779 - Heterocyclic sulfonamides: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Cytokinetics, Inc.

20120088780 - Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators: This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20120088781 - Famciclovir for the treatment of recurrent genital herpes labialis with a one day application: A method for the treatment of recurrent herpes labialis in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a period of one day.... Agent:

20120088782 - Lpa receptor antagonist: (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by... Agent: Ono Pharmaceutical Co., Ltd.

20120088783 - Chroman derivatives: wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical... Agent: Ampere Life Sciences, Inc.

20120088784 - Substituted aromatic compounds and pharmaceutical uses thereof: The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal... Agent:

20120088785 - New uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium: A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates... Agent:

20120088787 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and... Agent: Theravance, Inc.

20120088786 - Immediate release pharmaceutical compositions comprising oxycodone and naloxone: The present invention pertains to oral immediate release pharmaceutical compositions suitable for treating patients suffering from pain comprising oxycodone and naloxone or their pharmaceutically acceptable salts.... Agent:

20120088788 - Substituted imidazoles as bombesin receptor subtype-3 modulators: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.... Agent:

20120088789 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20120088790 - Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy: e

20120088791 - Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same: In one aspect, the invention relates to compounds having a general structure: Formula (I) which are useful as allosteric agonists of the M1 muscarinic receptor, synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurodegenerative diseases, including Alzheimer's... Agent: Vanderbilt University

20120088793 - Bicyclic compounds and methods of making and using same: Disclosed herein are compounds that may be modulators of 5-HT receptors, and methods of making and using same.... Agent: Nanotherapeutics, Inc.

20120088792 - Pyridin-2-yl methylamine derivatives for treating opiate dependence: s

20120088794 - Aminotetralin compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid... Agent: Theravance, Inc.

20120088796 - Compounds that inhibit (block) bitter taste in composition and use thereof: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the invention relates to the discovery of specific compounds and compositions containing that function as bitter taste blockers and the use thereof... Agent: Senomyx, Inc.

20120088795 - Factor xa inhibitors: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number... Agent: Millennium Pharmaceuticals, Inc.

20120088797 - 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the... Agent: Takeda Pharmaceutical Company Limited

20120088798 - Intramolecular hydrogen-bonded nitric oxide synthase inhibitors: Compounds and related compositions and methods as can be used to selectively inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases.... Agent:

20120088799 - Serotonin reuptake inhibitors: where X, Y, R1, R2, R3, R4, R4, and n are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20120088800 - 2-(substituted) (arylmethyl, aryloxy and arylthio))-n-(substituted pyridin-2-yl)-2-(substituted aryl) compounds as subtype-selective modulators of sphingosine-1-phosphate-3 (s1p3) receptors: The invention provides compounds represented by the formula (I), each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: wherein: A, m, n, p, a, X, Y and Z are defined in the specification. These compounds are useful for treating a disease or condition selected from... Agent: Allergan, Inc.

20120088801 - Pirfenidone therapy and inducers of cytochrome p450: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.... Agent: Intermune, Inc.

20120088803 - Control agent for soft rot and control method for the same: Provided is a novel control agent for soft rot and a novel control method for the same. The control agent for soft rot of a plant contains 3-chloro-N-(3-chloro-5-trifluoromethyl-2-pyridyl)-alpha,alpha,alpha-trifluoro-2,6-dinitro-p-toluidine as an active ingredient, which is applied to plant cultivation soil.... Agent: Ishihara Sangyo Kaisha, Ltd

20120088802 - Tricyclic compounds, compositions and methods: o

20120088804 - Clevidipine emulsion formulations containing antimicrobial agents: Pharmaceutical formulations comprising clevidipine and an antimicrobial agent exhibit a reduced propensity for microbial growth and provide increased convenience to health care workers administering clevidipine-containing formulations to patients.... Agent:

20120088805 - Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity: Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder... Agent: Ono Pharmaceutical Co., Ltd.

20120088806 - Seed treatment formulations and methods of use: The present invention generally relates to aqueous seed treatment formulations comprising a pesticidal agent, a polyvinyl alcohol (PVA), a graft copolymer, and a plasticizer. In one embodiment of the invention, PVA-compatible polymer emulsions are employed. The present invention also relates to uses of the disclosed compositions for protecting seeds from... Agent:

20120088807 - Interlaced method for treating cancer or a precancerous condition: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the... Agent: Tau Therapeutics LLC

20120088808 - Crystal forms of saxagliptin: The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.... Agent: Sandoz Ag

20120088809 - 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds: This invention provides new 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions.... Agent:

20120088810 - Thioxanthone ring system derivatives: wherein X is a substituent being one selected from a group consisting of halogens, wherein R1 is a substituent being one selected from a group consisting of sulfur and sulfur dioxide, wherein R2 is a substituent being one selected from a group consisting of C1˜C10 alkyl group, C3˜C10 branched alkyl... Agent: National Defense Medical Center

20120088821 - Method for treating atherosclerosis or restenosis using microtubule stabilizing agent: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or... Agent: The Government Of The United States Of America As Represented By The Secretary, Department Of

20120088822 - Low-dose doxepin for treatment of sleep disorders in elderly patients: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and... Agent: Somaxon Pharmaceuticals, Inc.

20120088823 - Composition and method for scalp and hair treatment: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness,... Agent: R-tech Ueno, Ltd.

20120088824 - Dosage unit comprising a prostaglandin analog for treating constipation: A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.... Agent: Sucampo Ag

20120088825 - Compounds with activity at estrogen receptors: d

20120088826 - Process for production of optically active amine derivatives: An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the... Agent: Takeda Pharmaceutical Company Limited

20120088827 - Oxabicyclo[4.1.0]hept-b-en-s-yl carbamoyl derivatives inhibiting the nuclear factor-kappa (b) - (nf-kb):

20120088828 - High surface activity pesticides: The present disclosure relates generally to the field of pesticides. In particular, the present disclosure relates to pesticide compositions that include high surface activity and slower drying surfactant pesticides.... Agent: Ecolab Usa Inc.

20120088829 - Formulations of ubiquinol and resveratrol esters: Disclosed herein are stabilized aqueous formulations comprising a ubiquinol ester/diester or resveratrol ester, and a micelle-forming surfactant, and methods for preparing the formulations. In one embodiment, the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 12 months.... Agent: Mycell Holdings Limited

20120088830 - Satiety-inducing composition: The present invention relates to the field of weight management. The invention particularly relates to a method for inducing satiety. In one of its embodiments, the present invention provides a method for inducing satiety in a human or an animal comprising administering to said human or animal an effective amount... Agent:

20120088831 - Thraustochytrids, fatty acid compositions, and methods of making and uses thereof: The present invention is directed to isolated thraustochytrid microorganisms as well as strains and mutants thereof. The invention is further directed to biomasses, microbial oils, compositions, cultures, methods of producing microbial oils, and methods of using the isolated thraustochytrids, biomasses, and microbial oils.... Agent:

20120088832 - Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and... Agent: Board Of Regents, The University Of Texas System

20120088834 - Crystalline forms of a 3-carboxypropyl-aminotetralin compound: The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.... Agent: Theravance, Inc.

20120088833 - Modified amino acid for the inhibition of platelet aggregation: A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof.... Agent:

20120088835 - Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to... Agent: Vanderbilt University

20120088836 - Use of a jasmonic acid compound for treating greasy skin: The invention relates to a method for cosmetically treating oily skin, including the topical application onto the skin of a composition containing a jasmonic acid compound in a physiologically acceptable medium.... Agent: L'oreal

20120088837 - Tetralin and indane derivatives and uses thereof: e

20120088838 - Methods for maintaining effective plasma concentrations of a pharmaceutical: The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os... Agent: Astellas Pharma Inc.

20120088839 - Composition for regulating cellular senescence comprising [n-2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide: The present invention relates to a composition for inhibiting cellular senescence, comprising N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide.... Agent:

20120088840 - Novel use of panduratin derivative or boesenbergia pandurata extract: The present invention relates to a novel use of a panduratin derivative or a Boesenbergia pandurata extract. More specifically, the invention relates to a composition for preventing and treating/relieving a metabolic disease selected from a group consisting of obesity, hyperlipidemia, hypercholesterolemia and diabetes, containing a panduratin derivative represented by Chemical... Agent: Newtree Co., Ltd.

20120088841 - Composition and a method of treating cns disorders and hyperpigmentation: The present invention relates to a method of treating CNS disorders, particularly Alzheimer's disease. The method comprise step of administering to a subject in need thereof a therapeutically effective amount of hydroxychavicol and/or its derivatives or a composition comprising hydroxychavicol and/or its derivatives optionally along with pharmaceutically acceptable excipients. The... Agent:

20120088842 - Methods for optimizing electroporation: Embodiments of the invention are directed to a technique for electroporation that allows for a delivery of long electrical pulses of high magnitude in highly conductive buffers and minimizes damage to cells undergoing electroporation.... Agent: Maxcyte, Inc.

20120088844 - Chain-extended polysiloxane crosslinkers with dangling hydrophilic polymer chains: The invention provide a class of linear chain-extended polysiloxane crosslinkers which comprises two terminal ethylenically unsaturated groups, at least two polysiloxane segments, and dangling hydrophilic polymer chains each covalently attached to a divalent organic radical separating each pair of adjacent polysiloxane segments. The present invention is also related to a... Agent:

20120088843 - Polymerizable chain-extended polysiloxanes with pendant hydrophilic groups: The invention provide a class of chain-extended polysiloxane crosslinkers which comprises (1) at least two polysiloxane segments, wherein each pair of adjacent polysiloxane segments is linked by one divalent organic radical which includes at least one pendant hydrophilic group (hydroxyl and/or carboxyl groups) or at least one dangling hydrophilic polymer... Agent:

20120088846 - Radiopaque shape-memory polymers: The present invention relates to shape-memory polymers which are distinguished by the fact that they comprise BiOCl pigments as X-ray contrast agents. Polymers doped in this way are used, in particular, in medical technology products, such as, for example, stiffening pins for the spinal column, tooth root cones, as bone... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20120088845 - Synthesis, capping and dispersion of nanocrystals: Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange... Agent:

20120088847 - Synthetic thickeners for cosmetics: Disclosed are inverse emulsions useful as thickeners for cosmetic formulations wherein the weight ratio between the aqueous phase and the oil phase is from 4:1 to 2:1 and containing from 20 to 70% by weight of an anionic acrylic polymer obtained by inverse emulsion polymerization of one or more anionic... Agent: Lamberti Usa, Inc.

20120088848 - Methods and compositions for controlled polypeptide synthesis: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for initiating the polymerization of aminoacid-N-carboxyanhydride (NCA) monomer by combining the monomer with an amido-containing metallacycle, for making self assembling amphiphilic block copolypeptides and related protocols for adding oligo(ethyleneglycol) functionalized aminoacid-N-carboxyanhydrides (NCAs)... Agent:

20120088849 - Oil-adsorbing composition, method for its production, and method for using the oil-adsorbing composition: Conventional dried materials have a low oil adsorption property and oil retention ability. Therefore, a dried material that has an excellent oil adsorbing property and oil retention ability has been desired. Accordingly, an object of the present invention is to provide an oil-adsorbing composition that has an excellent oil adsorption... Agent: Matsutani Chemical Industry Co., Ltd.

  
04/05/2012 > 98 patent applications in 83 patent subcategories. category listing, related patent applications

20120083439 - Method of preparing water-soluble and biodegradable antimicrobial agent: A method of preparing a water-soluble and biodegradable antimicrobial agent is provided. The method includes treating a polypeptide compound with sodium hypochlorite for at least 1 min, such that the polypeptide compound has at least one N-halamine group and has good antimicrobial effect. By using the method of the present... Agent: Far Eastern New Century Corporation

20120083440 - Methods and compounds for the targeted delivery of agents to bone for interaction therewith: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.... Agent: University Of Louisville Research Foundation, Inc.

20120083441 - Pharmaceutical compositions: Forms and formulations of VX-950 and uses thereof.... Agent: Vertex Pharmaceuticals Incorporated

20120083442 - Myostatin binding agents: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the... Agent: Amgen Inc.

20120083443 - Control of atp release by red blood cells and therapeutic applications thereof: The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCS treated with insulin accumulate significantly less cAMP and release significantly less... Agent: Saint Louis University

20120083444 - Emulsion method for preparing low residual solvent microparticles: The method disclosed herein comprises using a non-polar alkane in the continuous phase of an emulsion process to aid in the removal of dispersed phase solvent from the microparticles. The microparticles can further be subjected to a post-production treatment process, involving a non-polar alkane suspension and a rinse, to further... Agent:

20120083445 - Compositions containing hc-ha complex and methods of use thereof: Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the... Agent: Tissuetech, Inc.

20120083446 - Novel albumin-free factor viii formulations: An albumin-free Factor VIII formulation comprising, 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM... Agent: Baxter International Inc.

20120083447 - Novel therapeutic treatments using centhaquin: Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.... Agent: Midwestern University

20120083448 - Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use: Provided herein are Parathyroid hormone (PTH) peptides and parathyroid hormone-related protein (PTHrP) peptides (e.g., PTH analogs, PTHrP analogs), and related variants, chemical derivatives, fusion polypeptides, multimeric polypeptides, and peptidomimetics, peptoids, the like. Also provided are their use in methods for activating the PTH receptor in a cell (e.g., an osteoblast),... Agent: Van Andel Research Institute

20120083449 - Treatment for anxiety: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.... Agent: Nono Inc.

20120083450 - Cerebroprotein hydrolysate for treating brain injuries and neurodegenerative conditions effecting the brain: Cerebroprotein hydrolysate is administered intravenously and/or orally to help treat a range of brain injuries and neurodegenerative conditions effecting the brain including Traumatic Brain Injury (TBI), concussions, injuries resulting from automobile accidents, sports injuries, falls that impact the head, accidents and acts of violence that impact the head and brain... Agent:

20120083451 - Composition for improving brain function and method for improving brain function: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Pro-Pro-Y or a salt thereof, wherein... Agent:

20120083452 - Topical anesthetic uses of szeto-schiller peptides: Topical anesthetic compositions include Szeto-Schiller peptides and a dermatologically acceptable carrier, and optionally a vasoconstrictor and tyrosine. A method of providing local analgesia to the skin involves applying to skin the topical anesthetic compositions.... Agent:

20120083453 - Treatment using neublastin polypeptides: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.... Agent: Biogen Idec Ma Inc.

20120083454 - Eph receptor expression in tumor stem cells: The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.... Agent: Stemgen S.p.a.

20120083455 - Hyman serum albumin-sirna nano-sized carrier system: The human serum albumin-siRNA carrier system having the biodegradable covalent bond between the human serum albumin and the siRNA exhibits high siRNA delivery efficiency to a target site in the living body. Therefore, the human serum albumin-siRNA carrier system may allow siRNA for therapy to be efficiently delivered to a... Agent: Korea Institute Of Science And Technology

20120083456 - Methods of using il-31 to treat chronic obstructive pulmonary disease (copd): Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness... Agent: Zymogenetics, Inc.

20120083457 - Bortezomib formulations: A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.... Agent: App Pharmaceuticals

20120083458 - Methods and compositions for detecting and treating inflammatory disease: The invention features methods of diagnosing inflammatory disease based on the elevated presence microparticles (MP) expressing certain receptors. The invention also features methods of decreasing fibrosis in the liver by administering MP to subjects with liver fibrosis.... Agent:

20120083459 - Use of ganglioside to decrease propagation of malignant prostate cells: Uses of exogenous ganglioside to inhibit the propagation of prostate cancer cells are provided. Gangliosides regulate many cellular processes including cell death. The present disclosure assesses the role of ganglioside in prostate cell growth. Malignant prostate (PC-3) and control (RWPE-1) cells can be cultured with or without ganglioside treatment. Cells... Agent: The Governors Of The University Of Alberta

20120083461 - Agent for inhibiting peritoneal membrane thickening: (in this regard, however, R1, R2, R3, and R4 each represent a hydrogen atom or a lower alkyl group which may be the same as or different from each other; R5 represents a hydrogen atom, a lower alkyl group or a lower acyl group; X represents a mono-sugar residue or... Agent: Cci Corporation

20120083460 - Readily water-soluble isoquercitrin composition: Disclosed is a method for improving the solubility of isoquercitrin in water. Also disclosed is a readily water-soluble isoquercitrin composition which has improved solubility in water due to the method. Specifically disclosed is a method for preparing an isoquercitrin inclusion product, which comprises including isoquercitrin in γ-cyclodextrin in the proportion... Agent: San Ei Gen F.f.i., Inc.

20120083462 - Pharmaceutical anti-infective composition for inhalation: An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof.... Agent:

20120083463 - Insecticidal and fungicidal active compound combinations: The present invention relates to active compound combinations consisting, firstly, of a known halogen-substituted derivative (component A) and, secondly, of further known pesticidally active compounds (component B), which active compound combinations are suitable for controlling animal and microbial pests.... Agent: Bayer Cropscience Ag

20120083518 - Cancer treatment targeting brca1-iris: Patients identified as candidates at risk of developing aggressive cancer, including metastatic cancer, are determined based on the expression of BRCA1-IRIS. In one advantageous form, the expression of BRCA1-IRIS is quantified based on BRCA1-IRIS present in tumor cells of patients. The amount of BRCA1-IRIS expression can be quantified in any... Agent:

20120083519 - Methods for diagnosing and treating a renal disease in an individual: A method for diagnosing a renal disease in an individual, comprising: a) measuring the level of expression of c-mip in a renal sample of the individual; b) comparing the level of expression of c-mip to a predetermined value; and c) determining therefrom whether the individual is afflicted with a renal... Agent:

20120083521 - Aptamers as agonists: Nucleic acid aptamers are described herein which can transduce a signal into cells by crosslinking a cell surface molecule, thereby inducing of one or more biological activities by the cells; in serving as agonists.... Agent: Duke University

20120083520 - Ghrelin binding nucleic acids: The present invention is related to a nucleic acid antagonist of ghrelin.... Agent: Noxxon Pharma Ag

20120083522 - Modulation of inflammatory responses by factor xi: Disclosed herein are antisense compounds and methods for modulating Factor XI and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be ameliorated or prevented with the administration of antisense compounds targeted to Factor XI.... Agent: Isis Pharmaceuitcals, Inc.

20120083464 - Neuroprotective properties of 5'-methylthioadenosine: The present invention relates to the use of MTA, its pharmaceutically acceptable salts and/or prodrugs thereof as active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage, a neuroprotective medicament, a medicament for the regeneration of nerve cells, and a medicament... Agent: Proyecto De Biomedicina Cima, S.l.

20120083466 - Lipid conjugates in the treatment of allergic rhinitis: Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product... Agent:

20120083465 - Method for blocking ligation of the receptor for advanced glycation end-products (rage): A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The... Agent: University Of Utah Research Foundation

20120083467 - Deodorant compositions: A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent.... Agent:

20120083468 - Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis: A method of preparing a medical solution includes the steps of a) providing a solution having one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH of from 2.5 to 5.0, and b) terminal sterilization of the compartment and the contents... Agent:

20120083469 - Inhibitors of arginase and their therapeutic applications: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.... Agent: Mars, Incorporated

20120083470 - Inhibitors of tyrosine kinases and uses thereof: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated... Agent: Pharmacyclics, Inc.

20120083471 - Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same: The present invention relates to novel pharmaceutical compositions containing the same, and methods of use for a variety of therapeutically valuable uses including, but not limited to, treating obesity by inhibiting the activity of Glycerol 3-phosphate acyltransferase (GPAT).... Agent:

20120083472 - Pharmaceutical composition for promoting the healing of wounds and containing lysophosphatidic acid and an adenylyl cyclase inhibitor as active ingredients: The present invention relates to a pharmaceutical composition for promoting the healing of wounds, containing lysophosphatidic acid and an adenylyl cyclase inhibitor as active ingredients, and more particularly, to a pharmaceutical composition which contains an adenylyl cyclase inhibitor and which promotes the healing of wounds in senescent cells or aged... Agent: Snu R&db Foundation

20120083473 - Treatment of conditions by toll-like receptor modulators: Provided herein are methods for treating certain conditions, including fibrosis, inflammatory, and autoimmune conditions, with conjugated compounds having Toll-like receptor modulatory activity.... Agent:

20120083474 - Heterocyclic amides as modulators of trpa1: Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.... Agent:

20120083475 - Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to... Agent:

20120083476 - Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase: Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders,... Agent: Janssen Pharmaceutica Nv

20120083477 - Proteasome inhibitors and uses thereof: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being... Agent: Yeda Research And Development Co. Ltd.

20120083479 - Compositions comprising azelastine and methods of use thereof: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize... Agent: Meda Pharmaceuticals Inc.

20120083478 - Crystalline oxalate salts of a diamide compound: The invention relates to crystalline oxalate salts of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]-methyl}phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester. This invention also relates to compositions containing such a crystalline oxalate salt; methods of using such a crystalline oxalate salt to, for example, treat a pulmonary disorder; and to processes for preparing such a crystalline oxalate salt.... Agent: Theravance, Inc.

20120083480 - Controlled release delivery system for nasal applications: This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.... Agent:

20120083481 - Formulations of deoxycholic acid and salts thereof: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about... Agent: Kythera Biopharmaceuticals, Inc.

20120083482 - Inhibitors of vegf receptor and hgf receptor signaling: wherein A1 is sulfur, A3 is CH, A2 is CH, D is heterocycle, Z is oxygen, SO0-2 or NR, Ar is phenyl and G is not a ring, and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative... Agent: Methylgene Inc.

20120083483 - Inhibitors of hepatitis c virus replication: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production... Agent: Merck Sharp & Dohme Corp

20120083484 - Cyclopamine lactam analogs and methods of use thereof: The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.... Agent:

20120083485 - Noribogaine in the treatment of pain and drug addiction: The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such... Agent: Demerx, Inc.

20120083486 - Kit, composition, product or medicament for treating cognitive impairment: A kit, composition, product or medicament for treating cognitive impairment is provided, which includes a therapeutic agent for neurodegenerative disease and a heterocyclic compound represented by the following General Formula (I): or a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.... Agent: Zenyaku Kogyo Kabushikikaisha

20120083487 - Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury: Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor;... Agent:

20120083488 - Tetracyclic compound: o

20120083489 - Bis-pyridylpyridones as melanin-concentrating hormone receptor antagonists: The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes.... Agent:

20120083490 - Cytochrome p450 oxidase inhibitors and uses thereof: e

20120083491 - Combination of active substances with insecticidal properties: The invention relates to novel insecticidal active compound combinations comprising, firstly, compounds which act as insecticides on nicotinergic acetylcholine receptors as agonists and antagonists, and at least one active compound from the group of the anthranilamides, which combinations are suitable for protecting plants against attack by pests.... Agent: Bayer Cropscience Ag

20120083492 - Imidazopyrazines for use as kinase inhibitors: There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or... Agent: Centro Nacional De Investigaciones Oncologicas (cnio)

20120083493 - Small-molecule modulators of trp-p8 activity: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating... Agent: Dendreon Corporation

20120083495 - Compounds for the treatment of spinal muscular atrophy and other uses: Compounds useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift.... Agent: Department Of Health And Human Services

20120083494 - Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors: The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors.... Agent: Centre National De La Recherche Scient.

20120083496 - Isoxazole compound for the treatment of cancer: The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract,... Agent: Novartis Ag

20120083497 - Method for combating harmful fungi: The present invention relates to methods, use and compositions for combating harmful fungi and bacteria in plants. More specifically, it relates to methods and compositions for controlling, preventing, or treating plant pathogens using UV filters for combating phytotoxin-producing fungi and/or bacteria, in particular, for combating harmful fungi and/or bacteria producing... Agent:

20120083498 - Modulators of viral transcription, and methods and compositions therewith: Processes to treat human immunodeficiency virus (HIV) infection are included.... Agent:

20120083499 - Novel benzenesulfonamides as calcium channel blockers: o

20120083500 - Oxazolone and pyrrolidinone-substituted arylamides as p2x3 and p2x 2/3 antagonists:

20120083501 - Compounds for treating neurodegenerative diseases: The invention provides novel tricyclic compounds of Formula I′ that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.... Agent:

20120083502 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20120083503 - Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer: This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur/gimeracil/oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene.... Agent: Kinki University

20120083504 - Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.... Agent:

20120083506 - Reduction of opioid blood fluctuations: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.... Agent: Ethypharm

20120083505 - Use of opioid receptor antagonists for acute treatment of paraphilic arousal states: The present invention is directed to an opioid receptor antagonist or a pharmaceutically acceptable salt thereof for use in a method of acute treatment of paraphilic sexual arousal states in patients suffering from paraphilia.... Agent:

20120083507 - Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy: Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to... Agent: Medicis Pharmaceutical Corporation

20120083508 - Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain: Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20120083509 - Synergistically active mixtures of alpha,omega-amino alcohol enantiomers, preparation thereof and use thereof in insect- and mite-repellent formulations: What are described are insect- and mite-repellent compositions comprising at least 2 enantiomers selected from the group of 1-[(S)-sec-butyloxycarbonyl]-2-(S)-(2-hydroxyethyl)piperidine (referred to hereinafter as S,S), 1-[(R)-sec-butyloxycarbonyl]-2-(R)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as R,R), 1-[(S)-sec-butoxycarbonyl]-2-(R)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as S,R), 1-[(R)-sec-butyloxycarbonyl]-2-(S)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as R,S), excluding the racemate mixture thereof,... Agent: Saltigo Gmbh

20120083510 - Perfluorocarbons for use in treating pruritus: The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a... Agent:

20120083513 - 3-substituted-8-substituted-3h-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use: e

20120083511 - Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol: The present invention provides crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol useful in the treatment of cancer.... Agent: Eli Lilly And Company

20120083512 - Pharmaceutical product for injection: The claimed subject matter is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the... Agent: Nycomed Gmbh

20120083514 - Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug: The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R1, R2, R3, R4, X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The... Agent:

20120083515 - Bioadhesive gel based on hydroxyethylcellulose: Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent.... Agent: Mitech-idea S.r.l.

20120083516 - Nasal sinus spray for treatment of sinus headache and method of using same: Disclosed is a nasal spray containing the combination of a vasoconstrictor and a topical local anesthetic.... Agent:

20120083517 - Polymorphs of saxagliptin hydrochloride and processes for preparing them: The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride.... Agent:

20120083523 - Medical devices having polymeric regions with copolymers containing hydrocarbon and heteroatom-containing monomeric species: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes the following: (a) one or more unsaturated hydrocarbon... Agent: Boston Scientific Scimed, Inc.

20120083524 - Oral composition comprising dha and genistein for enhancing skin properties: Composition for oral consumption in the form of a substantially 5 homogeneous aqueous emulsion, suspension or dispersion comprising genistein and docosahexaenoic acid (DHA) and less than 1% by weight of soy protein, wherein the weight ratio of genistein to DHA is in the range of from 1:100 to 1:1, the... Agent: Conopco Inc., D/b/a Unilever

20120083525 - Composition for preventing or treating obesity-related diseases mediated by the activation of ampk and including 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignans as active ingredients: The present invention relates to a 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan compound which activates nutmeg-derived AMP-activated protein kinase (AMPK), and to a composition including same as active ingredients for preventing and treating metabolic syndromes such as obesity. More particularly, the present invention relates to an AMPK-activating compound comprising one of the 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan-based... Agent: Amorepacific Corporation

20120083527 - Anticancer agents: The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described.... Agent: The Regents Of The University Of California

20120083526 - Synthesis of 1-(2,3-dihydrobenzofuran-4-yl)ethanone as intermediate in the preparation of ramelteon: The present invention relates in general to the field of organic chemistry and in particular to the preparation of 1-(2,3-dihydrobenzofuran-4-yl)ethanone, an intermediate in preparation of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide, i.e. ramelteon.... Agent: Lek Pharmaceuticals D.d.

20120083528 - Novel protein kinase modulators and therapeutic uses thereof: The present invention provides new tyrphostin derivatives acting as protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, and/or which directly or indirectly affect proteins in the PTK-mediated signal transduction pathway, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions,... Agent: Novotyr Therapeutics Ltd.

20120083529 - Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders: The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative, preferably methyl jasmonate. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses... Agent: Sepal Pharma Ltd

20120083530 - Thermally stable oil-in-water emulsions containing an oil that contains polyunsaturated fatty acids: The present invention relates to thermally stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of −40° C., and are free from... Agent: Martek Biosciences Corporation

20120083531 - Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining: The present invention relates to pharmaceutical compositions suitable for inhalation, comprising as an active ingredient calcium lactate or calcium citrate. The invention also relates to methods of treating, preventing, and reducing the spread of an infection of the respiratory tract, comprising administering a pharmaceutical composition that comprises calcium lactate or... Agent:

20120083532 - Novel uses: The present invention relates to the use of a compound represented by the general formula (I), and pharmaceutically acceptable salts thereof, wherein: n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an... Agent:

20120083533 - Use of amides of mono- and dicarboxylic acids in the treatment of renal diseases: A therapy for renal diseases, in particular renal diseases which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, the present invention... Agent:

20120083534 - Ophthalmic and contact lens solution: An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit.... Agent:

20120083535 - Adhesive mixture for transdermal delivery of highly plasticizing drugs: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.... Agent:

20120083536 - Antimicrobial adhesive system: An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated... Agent:

20120083537 - Tcd based hydrophilic polyurethane dispersions:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.92013 seconds

PATENT INFO